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Minutes of the Meeting 





Purpose:  Discuss on-going work in biorepositories and Amyotrophic Lateral Sclerosis (ALS) 
research and provide comments on a proposal for a biorepository of tissue samples to 






Robert Kingon, Facilitator 
Atlanta, Georgia 
 
At 9:00 a.m., Robert Kingon welcomed the group to the meeting.  He asked that those present 
introduce themselves.  Following the introductions, he offered housekeeping notes and 





Kevin Horton, DrPH, MSPH 
Chief, Surveillance and Registries Branch 
Division of Health Studies 
Agency for Toxic Substances and Disease Registry 
 
Dr. Horton added his welcome and presented an overview of the National ALS Registry, 
explaining that over the last 5-6 years, a number of people have worked very hard to bring the 
registry to fruition.  They have made a great deal of progress and are now seeking ways to 
enhance the registry, including the creation of a bioregistry.  He encouraged the group to speak 
freely as they offered feedback. 
 
The Agency for Toxic Substances and Disease Registry (ATSDR) is a federal agency of the US 
Department of Health and Human Services (HHS) and is a sister agency of the Centers for 
Disease Control and Prevention (CDC).  ATSDR focuses on environmental health issues, 
especially as they relate to exposure to toxic substances.  The agency is located in Atlanta, 
Georgia and engages in a number of activities, including health studies; emergency response; 
applied research; and health surveillance and registries.  ATSDR operates several registries. 
 
  




Background and History of the National ALS Registry 
 




The National ALS Registry was created for a number of reasons.  ALS is a devastating disease.  
Approximately 80% of cases die within 2-5 years of diagnosis.  Therefore, it is critical to have a 
registry to understand not only who has ALS, but also why people get ALS.  The incidence and 
prevalence data on ALS are not reliable, as they come from small-scale studies and are 
extrapolated to the US population.  The National ALS Registry allows for national-level 
incidence and prevalence of ALS. 
 
Congress enacted the ALS Registry Act in October, 2008.  The act directs ATSDR to create and 
maintain the registry, but does not make ALS a reportable disease.  The purpose of the registry 
is to describe the incidence and prevalence of ALS; describe the demographics of ALS patients, 
and examine risk factors for the disease. 
 
To evaluate the feasibility of using existing data to create the National ALS Registry, ATSDR 
conducted 4 pilot projects to identify individuals in the national databases who have been 
treated, or would have been treated, for any motor neuron disease (MND) by a health care 
provider in the local catchment area; review medical records from local data sources to 
determine correct diagnosis; determine which ICD9 and procedure codes in the national 
databases are most reliable for identifying ALS cases; and develop algorithms to identify true 
cases of ALS. 
 
Using medical record review as a gold standard, ATSDR built algorithms to identify true cases 
of ALS.  The creation process was trial and error and, with changes, the ultimate algorithm 
yields the best sensitivity and specificity.  Several attributes were identified:  ALS in more than 
one year; RILUTEK®, although not all ALS patients take Rilutek; and frequent visits to a 
neurologist.  Records were ruled out if there were no visits to a neurologist and no ALS visits. 
 
ATSDR secured databases from Medicare, Medicaid, and the US Department of Veterans 
Affairs (VA) and applied the algorithms to the databases, allowing them to tease out true ALS 
cases, cases that are clearly not ALS, and cases with unclear ALS status.  The VA databases 
are the Veterans Health Administration (VHA) and the Veterans Benefits Administration (VBA) 
databases. 
 
A Web-based portal for self-identification is hosted on the CDC server, which is highly secure.  
This portal is critical, given that all ALS patients are not reflected in the Medicare, Medicaid, and 
VA databases.  Further, there is a time lag of up to 3 years or more associated with those 
databases, where the Web portal allows for efficient, real-time capturing of ALS cases.  The 
portal allows ATSDR to capture epidemiological information through brief risk factor surveys.  It 
also provides other educational material for physicians and health professionals.  As 
publications emerge, they will be made available through the portal. 
 
The current methodology for the National ALS Registry includes applying the algorithm to the 
Medicare, Medicaid, and VA databases, which represent approximately 90 million people in the 
US, and self-registration through the Web portal.  All ALS patients are encouraged to access the 
Web portal, even if they are included in one of the larger databases.  Self-enrollment improves 
efficiency and also allows participants to answer risk factor questions.  The Web portal was 
launched in 2010, and the response has been very good so far, with thousands of risk factor 
surveys already completed.  The challenge with any registry is to sustain momentum and 
awareness about it, especially for those who are newly diagnosed. 
 
  




The National ALS Registry receives information as follows: 
 
National ALS Registry Flowchart































Potential ALS patients are re-evaluated when subsequent years of data are available to 
determine whether they are true ALS cases.  The validation questions in the Web portal are the 
same questions used by the VA when they operated their ALS registry in the early 2000s.  
ATSDR worked with Stanford University to develop the risk factor modules and to convert them 
to an electronic, self-administered format.  These modules are noted in the literature as potential 
associations with ALS: 
 
 Demographics 
 Military History 
 Lifetime Occupational History 
 Smoking and Drinking History 
 Physical Activity 
 Family History of ALS and Neurodegenerative Diseases 
 ALS Functional Rating Scale-Revised (ALSFRS-R), self-administration version 
 
The ALSFRS-R assesses disease progression and quality of life, so participants in the registry 
are asked to complete that module twice a year.  The other modules are completed only once. 
 
New components are planned for the National ALS Registry.  Additional risk factor surveys are 
in development and should be available in late 2012 or early 2013.  A clinical research 
notification system will aid researchers who seek participants in studies.  Under this system, 
researchers will submit proposals for studies or clinical trials to ATSDR.  The application 
process will be online and will require appropriate Institutional Review Board (IRB) and Food 
and Drug Administration (FDA) approvals, where applicable.  If the project is approved, ATSDR 
will contact members of the Registry who fit the study population and inform them about the 
project, provide its recruitment materials, and contact information for the researchers.  Patients 
can then contact the researchers if they are interested in participating.  This feature of the 
Registry is expected to be live in April 2012. 
 
  




Other new plans for the Registry include state- and metropolitan area-based surveillance 
projects, which will help test the completeness of the registry.  These active case-finding 
approaches to ALS include direct contact with neurologists in the catchment areas.  ATSDR will 
be able to compare that information from catchment areas with information in the National ALS 
Registry to assess the completeness of the Registry data.  If cases are not being captured, then 
ATSDR will adjust the methodology.  These surveillance projects are in areas that over-
represent different demographic groups and should provide insight into how ALS affects various 
sub-populations such as African Americans, Latinos, and Asian Americans.  The addition of a 
bioregistry would make the National ALS Registry world-class.  ATSDR has expertise in 
registries, but not necessarily in bioregistries.  Dr. Horton expressed his hope that the group 




 Dr. Brujin commented on the family history module in the self-enrollment portal, noting that 
family history and genetics can change over time.  The questionnaire includes general 
questions about MNDs, as opposed to ALS specifically. 
 
 Dr. Horton said that some of the questions mention specific MNDs, including Parkinson’s 
disease and ALS. 
 
 Dr. Brujin asked whether the clinical research notification system will allow researchers to 
access participants for work on chromosome-9. 
 
 Dr. Horton replied that the Registry will be available for such work and can provide subsets 
of populations for recruitment. 
 
 Dr. Kamel said that the Medicare database will include mostly older people, which is the 
population with the most ALS cases.  However, some of the more interesting cases are in 
younger populations.  She wondered how ATDSR would reach a more diverse age 
population. 
 
 Dr. Kaye clarified that persons with ALS become automatically eligible for Medicare, 
regardless of age.  The algorithm takes this eligibility into account.  The VA automatically 
provides service-related disability related to ALS at any time. 
 
 Dr. Horton added that the registry merges the Medicare and Medicaid databases, matching 
Social Security Numbers to eliminate duplicates. 
 
 Dr. Kasarskis pointed out that the ALSFRS-R is a measure of function and not a measure of 
quality of life per se.  He asked whether specific quality of life measures, such as 
depression, were included in the questionnaires. 
 
 Dr. Horton acknowledged that the ALSFRS-R does not address quality of life questions and 
said that ATSDR is always interested in entertaining new ideas for modules.  They have 
worked with the ALS Research Group (RG), which has created clinically-based questions for 
ALS patients to answer.  The Office of Management and Budget (OMB) is concerned that 
participants in registries are not overburdened by questionnaires, but ideas from 
researchers, physicians, and patients are welcomed. 
 




 Dr. Kasarskis asked whether a relative or friend of an ALS patient can interact with the Web 
portal on behalf of the person with ALS. 
 
 Dr. Horton responded that ALS patients can receive assistance in completing the 
questionnaires, but it is important that they read the consent form and that their assistants 
not complete the questionnaires for them, but with them. 
 
 Dr. Horn asked whether information from the registry could be reported back to participants, 
emphasizing that sharing information can help engage participants and improve participation 
rates. 
 
 Dr. Horton said that it is important to analyze and publish the data that they collect so that 
they can share information with their patients and stakeholders.  They are not yet at a point 
where they have information to share, but they will keep participants informed via the Web 
portal and possibly through emails and Webinars.  The Registry is a collaborative effort, and 
they rely on their partners who interact with ALS patients on a daily basis.  They are working 
with the ALS Association and the Muscular Dystrophy Association (MDA) and their affiliates 





Wendy Kaye, PhD 
Senior Epidemiologist 
McKing Consulting Corporation 
National ALS Registry Program 
Agency for Toxic Substances & Disease Registry 
 
Dr. Kaye expressed her pride in the National ALS Registry and its progress in a relatively short 
amount of time.  She reminded the group that this meeting would focus on the best way to 
create a biorepository in association with the National ALS Registry.  A draft protocol was 
created to generate conversation, and the group’s input would be critical, particularly regarding 
which specimens should be collected and the population size for a pilot to test the feasibility of 
the biorepository.  She stressed that rather than focusing on logistics and how the specimens 
will be used, they should focus on the scientific aspects of the specimens that should be 




Advances in ALS Research 
 
Amelie Gubitz, PhD  
Program Director, Neurodegeneration 
National Institute of Neurological Disorders and Stroke (NINDS) 
National Institutes of Health (NIH) 
 
Dr. Gubitz thanked ATSDR for the opportunity to present exciting new discoveries in ALS 
research, highlighting the importance of doing research using human biospecimens.  ALS 
research is a shared mission across multiple institutes at the National Institutes of Health (NIH).  
NIH includes 27 different institutes and centers, at least 10 of which have investment in ALS 
Purpose and Goals of the Meeting 
 
Why Do We Need an ALS Biorepository? 
 




research, extramurally and intramurally.  The National Institute of Neurological Disorders and 
Stroke (NINDS) is the lead institute for ALS research at NIH, but the contributions of other 
institutes are important and tend to focus on specific aspects of the disease.  In fiscal year (FY) 
2011, NIH’s overall investment in ALS research was approximately $44 million. 
 
NINDS supports investigator-initiated, peer-reviewed ALS research.  The research community is 
in the best position to identify scientific opportunities and to design research projects that take 
advantage of those opportunities.  Project ideas are vetted by peer reviews, study sections, and 
the NINDS Advisory Council.  Approximately half of NINDS’s investment in ALS is focused on 
projects that explore the molecular pathogenesis of the disease.  They are also interested in the 
etiology of ALS, studying genetics and epidemiology.  NINDS invests in preclinical therapy 
development for ALS, which includes biomarker research as well as clinical trials. 
 
NINDS also supports resources for ALS research, including the NINDS Repository, which is a 
biobank of DNA samples and cell lines with associated clinical data for multiple neurological 
disorders, including ALS.  In collaboration with the scientific ALS community, NINDS developed 
and launched Common Data Elements for ALS Clinical Research.  The goal of these Common 
Data Elements is to standardize clinical data sets to facilitate data mining and for meta-analysis.  
NINDS has a dedicated investment in the exciting research area of the development of induced 
pluripotent stem cell strategies for ALS. 
 
Advances in the molecular pathology of ALS have also been exciting.  It has long been known 
that intracellular inclusions of ubiquitinated protein in affected tissues are a hallmark of ALS and 
other neurodegenerative disorders.  In terms of ALS, the protein content of these inclusions 
remained enigmatic for a long time.  In 2006, a landmark study from the University of 
Pennsylvania assessed autopsy tissue from patients who suffered from sporadic ALS and 
ubiquitin-positive Frontotemporal Lobar Degeneration (FTLD-U).  The researchers were able to 
show that the protein in these inclusions is Transactivation Response (TAR) DNA binding 
protein (TDP)-43.  This discovery came as a surprise to the ALS field, as TDP-43 had previously 
not been associated with neurodegenerative disease, and all that was known about the protein 
is that it likely has important roles in cellular RNA metabolism. 
 
Since the original study, this finding has been confirmed and replicated by research teams 
across the world.  This pathology is now referred to as TDP-43 proteinopathy.  TDP-43 
inclusions are present in spinal cord tissue and brain tissue of most cases of sporadic and 
familial ALS as well as FTLD-U.  The inclusions are absent from familial ALS that is linked to 
mutations in the superoxide dismutase 1 (SOD1) gene.  This is important, as recent ALS 
research has focused on SOD1-linked ALS.  It seems that there are important molecular 
differences, although this work is evolving. 
 
Evidence is accumulating that ALS and FTLD-U are disorders on a clinical and pathological 
spectrum with overlapping molecular pathogenesis.  This may have important therapeutic 
implications.  Further, the presence of TDP-43 inclusions suggests that cytoplasmic protein 
aggregations and/or defects in RNA metabolism may play important roles in ALS and FTDL-U. 
 
Several milestones have been achieved in ALS gene discovery.  ALS is largely a sporadic 
disease, with only 5% to 10% of cases showing clear familial inheritance.  The first 
breakthrough in ALS genetics research was attained in 1993, when mutations in SOD1 were 
found to be causative in about 15% of familial ALS cases.  Since 2000, over 15 additional 
familial ALS genes have been identified.  When the TDP-43 positive pathology was discovered, 
researchers found mutations in the gene that encodes TDP-43  in some ALS families, as well as 




mutations in a highly-related gene, FUsed/Translocated in LipoSarcoma (FUS/TLS).  The most 
recent additions to the list of ALS are Ubiquilin-2 (UBQLN2) and chromosome 9 open reading 
frame 72 (C9ORF72).  Since ALS is a largely sporadic disease, researchers have used 
genome-wide association studies in order to search for genetic risk factors for the disease.  This 
approach has not revealed major risk alleles for ALS, but in some populations, the studies 
identified a “hot spot” for linkage on chromosome 9.  It is now known that this is the locus of the 
C9ORF72 gene. 
 
In the summer of 2011, Teepu Siddique and colleagues reported that mutations in UBQLN2 
cause dominant x-linked ALS.  Although the mutations are rare, this finding is important since 
UBQLN2 is involved in cellular protein degradation and turnover.  The finding suggests that 
defects in protein recycling leads to the death of motor neurons.  This pathway of disease is 
plausible, as there are protein aggregates in affected tissues. 
 
In October 2001, two back-to-back articles were published in the journal Neuron.  One article 
was authored by an international consortium of scientists led by Bryan Traynor, and the other 
was authored by Rosa Rademakers and colleagues.  Both teams were independently able to 
pinpoint the genetic mutation on chromosome 9.  Previous studies had suggested that there 
was an association between ALS and a genetic lesion on the short arm of chromosome 9, but 
for a long time, the nature of this lesion remained elusive.  Only through elegant detective work 
were both teams able to show that the nature of the lesions is a long repeat expansion of a 
sequence motif in an intronic region of an unknown gene called C9ORF72.  The C9ORF72 
repeat expansions are the most common cause of ALS and frontotemporal dementia (FTD) 
identified to date.  This type of genetic abnormality is enriched in families where ALS and FTD 
co-occur or where individuals suffer from symptoms of both disorders.  The link between the two 
diseases is very important.  The nature of these repeat expansions is similar to other diseases, 
including myotonic dystrophy.  This commonality could be important for therapeutic purposes. 
 
Regarding disease mechanisms of ALS, when mutations in SOD1 were found to be a genetic 
culprit of the disease, research teams developed mutant SOD1-based animal models.  These 
models have been extremely valuable in delineating the molecular pathogenesis of SOD1-linked 
ALS.  Mutant SOD1-mediated toxicity in ALS is non-cell autonomous, which means that it 
affects cells beyond motor neurons: “the neighborhood matters.”  Further, disease is not caused 
by loss of enzymatic activity of the SOD1 protein, but by a toxic gain-of-function mechanism.  It 
appears that mutant SOD1 disrupts multiple cellular processes in multiple cell types.  Once 
mutant SOD1 begins to misfold, cells experience a multi-pronged crisis.  It is not known whether 
the cellular pathways of disease run in parallel, whether there are 1 or 2 important pathways, or 
whether there are important points of convergence upstream of motor neuron degeneration. 
 
A major question in the field is whether the suspected disease mechanisms of SOD1-linked ALS 
are also relevant to other forms of the disease, especially sporadic ALS.  This question needs to 
be addressed by research that employs human biospecimens, including post-mortem tissues, 
cell lines or primary cells, and biofluids.  The scientific community recognizes this need.  Brian 
Kaspar and his colleagues derived astrocyte cells from fresh autopsy tissues from ALS patients 
who had suffered from sporadic ALS or familial SOD1-linked ALS.  These astrocytes are toxic to 
normal motor neurons in cell culture, and the toxicity is dependent on the expression of SOD1.  
This finding is surprising in the context of sporadic ALS.  The research community is discussing 
the finding, and it warrants confirmation.  This type of study showcases the importance of 
conducting research using human biomaterials. 
 




There are a number of opportunities and challenges for ALS research in 2012 and beyond.  
Genetics and neuropathological research have provided clues about the molecular 
pathogeneses of ALS.  There are likely a number of complexities and heterogeneity, which 
presents a major challenge for the field but it also offers multiple points for therapeutic 
intervention.  The community seeks therapeutic targets were there is convergence between the 
different forms of ALS.  Additionally, the etiology of sporadic ALS remains unexplained.  It is 
anticipated that environmental, behavioral, and genetic risk factors may be involved.  Another 
challenge is the urgent need for better and additional biomarkers in ALS to expedite diagnosis, 
to help define prognosis, and to improve clinical trials.  Such biomarkers can be derived from 
human biofluids, which highlights the need for high-quality and accessible biofluid collections.  
While animal models are important research tools in the field of ALS, the models do not fully 
recapitulate human disease, especially sporadic ALS.  Alternative model systems that are 
based on human biomaterials are needed. 
 
It is clear that research using human biospecimens has greatly advanced the understanding of 
ALS.  Therefore, there is a continued need for high-quality and broadly accessible biofluid 
samples and post-mortem tissue for ALS research.  The ALS field has several biobanks, but 
many of them are relatively small and are typically housed at academic institutions.  They may 
only have limited accessibility.  With a few exceptions, they also often lack the funding or 
capacity for broader sample distribution.  The National ALS Registry Biorepository would 




 Dr. Vaught asked how “high-quality” is defined in this context. 
 
 Dr. Gubitz replied that “high-quality” refers to following standard operating procedures 
(SOPs) for the collection and storage of biosamples.  Many research labs work on these 
issues actively.  In particular, the Northeast ALS Consortium (NEALS) Biorepository has put 
a great deal of effort into ensuring that the samples are collected in a homogenous fashion, 
that the quality of the samples is preserved, and that the samples are tracked correctly so 
that distribution and retrieval is transparent and done in an informative way.  It is also 
preferable to associate the biosamples with clinical data sets.  The NINDS Common Data 
Elements  help to harmonize the clinical data sets that are associated with samples. 
 
 Dr. Vaught said that the answers to those questions will help them decide whether to collect 
blood, saliva, or both. 
 
 Dr. Gwinn asked how the use of the Common Data Elements is promoted throughout the 
clinical community. 
 
 Dr. Gubitz answered that the elements were developed in collaboration with ALS clinicians.  
The elements are accessible through the NINDS website.  A team in their clinical office is 
charged with raising awareness about the elements, but it is a challenge.  The elements are 
only helpful if they are adopted by the community.  They include a great deal of detail, which 
can be a burden. 
 
 Dr. Gwinn asked whether any journals were promoting meta-analysis. 
 
 Dr. Gubitz replied that there have been efforts in that arena.  Common Data Elements have 
been developed for a range of diseases, and the effort is active. 





Rationale for ALS Biorepository 
 
Lucie Bruijn, PhD 
Chief Scientist 
The Amyotrophic Lateral Sclerosis Association 
 
Dr. Brujin expressed her gratitude for being invited to participate in the meeting, and her 
excitement about the potential for a National ALS Biorepository.  She offered an overview of the 
importance and value of the biorepository.  It will be critical to integrate and combine with 
existing resources, as it is unlikely that one biorepository will be able to do everything.  There 
are well-established networks in the ALS community, and a great deal of work has already been 
accomplished on SOPs. 
 
The discovery of new genes has changed the field of ALS significantly, and the discoveries 
would not have been possible without biorepository collections.  There are challenges in long 
clinical trials, and the ALSFRS is a good indicator of change over time.  Survival is still the key 
endpoint, and the trials are very long and expensive; therefore, it is difficult to incentivize 
industry participation.  Biomarkers and repositories are critically important for discovery, 
diagnostics, and clinical trials.  Understanding the disease mechanism is critical for finding 
better treatments. 
 
The NINDS repository represents a successful partnership with many ALS Association (ALSA) -
certified centers, MDA chapters, and persons with ALS (PALS).  At one time, the NINDS 
repository only included 4-5 ALS samples.  Now, the repository includes 2000 samples, which 
reflects the support and energy of the ALS community which is committed to using the samples.  
When a repository is built, it must be useful.  ALSA supported work to search for the 
Apolipoprotein E (APOE) for ALS, and that work has been a testament to the complexity of ALS 
and the diversity of samples in the repository.  Perhaps small gene changes in sporadic ALS 
cannot be discerned by current technology.  It is important to collect appropriate similar data.  
ALSA has been able to work globally to look at samples, and there have been indications of an 
interesting locus that determines onset of ALS.  The critical studies of chromosome 9 would not 
have been possible without biorepositories.  Chromosome 9 has major implications for familial 
as well as sporadic ALS.  Human brain and spinal cord samples are critical to ALS research.  
ALS is a spectrum, as illustrated below: 
 
Clinical and Pathological Relationships 












This mapping work was possible through work with brain tissue and the identification of various 
pathologies.  The question of where SOD1 fits into the picture is still open.  The chromosome 9 
cases indicate different localizations of pathologies where FTLD dominates and where ALS 
dominates.  Having well-characterized tissue from these populations will add to understanding 
of chromosome 9 mutations. 
 
Another study assessed the SOD mutation in mouse models.  The study found that 
phosphorylated Neurofilament H (pNF-H) is a good marker for ALS disease progression, as 
levels in blood increased over time.  The question was then applied to human tissue through a 
partnership with Dr. Kevin Boylan at the Mayo Clinic.  In ALS patients, there is a higher level of 
pNF-H as compared to controls.  Other studies have confirmed the relevance of pNF-H.  It may 
be important to study a combination of markers for ALS, rather than a single marker.  pNF-H 
and C3 correlate strikingly with ALS compared to other disease areas.  These examples 
highlight the importance of sharing samples among groups to validate findings and to make 
comparisons between animal models and human tissue. 
 
A range of excellent animal models is available to contribute to the understanding of the ALS 
disease mechanism.  The model systems allow researchers to examine many aspects of ALS.  
In particular, the animal models allow for work in real time, where human tissue is an endpoint.  
Without combining the work in animal models with work in human tissue, it will be difficult to 
prove that the pathways discovered are important to ALS.  An abundance of interesting 
pathways are discovered in animal models, and the research community is challenged to 
validate those pathways in human tissues so that they can hone in on the pathways that are 
meaningful and potentially therapeutically relevant. 
 
A new study by Piera Pasinelli and her colleagues focuses on the question of whether SOD1 
may also play a role in sporadic ALS, as opposed to only in familiar ALS.  This question is 
critical for the field, as clinical trials are on-going which shut down the production of SOD1 in 
mutant cases and familial ALS.  If SOD1 is relevant in sporadic cases as well, then such 
therapies can be expanded.  The Pasinelli study could not have been completed without well-
defined human tissue.  The over-oxidized forms of SOD1 were not found in all ALS cases, but 
were found in bulbar cases in particular.  The study is interesting, but needs to be replicated 
using clearly-defined and well-characterized samples.  The work was conducted in 
lymphoblasts. 
 
Good sources of tissue include cerebrospinal fluid (CSF), plasma, lymphoblasts, brain and    
spinal cord, and fibroblasts.  Collaboration with existing collections is critical, and it is also 
important to assure standardization and appropriate clinical and environmental data.  Otherwise, 
studies may be fragmented.  Access to the biorepository is vitally important because many 




 Dr. Bouzyk asked about environmental components and methylation signatures. 
 
 Dr. Brujin replied that there is growing interest in this area in the field, although ALSA has 
not funded any work in it.  NIH may have seen more approaches to it.  The right tools are 
needed to address those questions. 
  







Northeast ALS Research Consortium 
 
James Berry, MD, MPH 
Neurology, Massachusetts General Hospital, East 
Charlestown, Massachusetts 
 
Robert Bowser, PhD 
Director, Gregory W. Fulton ALS and Neuromuscular Research Center 
Professor, Divisions of Neurology and Neurobiology 
Barrow Neurological Institute and St. Joseph's Hospital and Medical Center 
Phoenix, Arizona 
 
Dr. Berry pointed out that biobanking is important because of the potential to increase the 
quality and number of samples that are available, and to link clinical information.  Biomarker 
discovery has numerous potential benefits as well, including facilitating clinical research by 
hastening diagnosis and entry into studies.  A biomarker can potentially and ideally serve as a 
surrogate endpoint, and biomarkers can inform research into ALS pathophysiology.  A 
biomarker serving as a surrogate endpoint does not necessarily need to speak to the underlying 
pathophysiology of the disease; rather, the biomarker could be something that changes over 
time in a predictable manner. 
 
The overarching problem with earlier biobanks and biorepositories is that patient accrual for 
sample collection is slow and can limit biomarker studies.  As a result, a number of concessions 
are made as collection schemes for biomarker research are created.  Sample sizes in these 
studies tend to be small, and the sample collection and storage techniques have not been 
uniform, which can degrade the quality of the samples.  There can be a lack of adequate clinical 
information and disease mimics.  Therefore, there is often a lack of validation studies. 
 
Biobanks can be built with these concerns in mind, utilizing strategies to overcome the 
limitations.  For instance, a large biobank can be built to hasten access to pre-collected 
samples.  Multicenter studies can be used to boost the number of samples in the biobank.  
Rigorous SOPs can increase procedural quality.  Clinical information can be included with 
samples in the database, and appropriate disease mimics can be included.  Samples should be 
shared with ALS scientists, allowing for validation of research and opportunities for new 
thinking.  Alzheimer’s disease researchers have worked hard to build multicenter studies and to 
standardize collection procedures.  This work resulted in the identification of CSF biomarkers.  It 
took a large, concerted effort on the part of the field to confront the challenges in Alzheimer’s 
disease research, many of which are similar to the challenges that ALS research faces. 
 
The NEALS Biorepository was built with the goal of creating a large, high-quality, standardized 
biofluid repository.  Its principal aims are to reduce pre-analytical sample variation through the 
application of SOPs, link clinical data, identify and validate biomarkers, share samples, and 
maintain and expand the biorepository. 
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The first study that was actively designed to recruit patients and collect samples is called “BIO 
001.”  Four groups of people were recruited for the study: 
 
 Persons with ALS 
 Persons with a pure upper or lower MND that could not yet be categorized as ALS 
 Diseases mimics 
 Healthy controls 
 
The study built in a 7-day medication washout for non-essential medications to further reduce 
pre-analytic sample variation.  At the first visit, demographic and clinical information was 
collected, and the ALSFRS was administered and databased.  The samples included blood for 
serum and plasma, and whole blood for DNA and CSF, from those patients who agreed.  
Patients in the motor neuron groups had follow-up visits at 6, 12, and 18 months for ALSFRS 
and serum and plasma collection.  There was no longitudinal CSF collection.  A telephone 
follow-up was conducted every 6 months thereafter. 
 
Thirty centers were involved in this study, and it was clear that technical factors could introduce 
enough variability to wash out potential disease variability.  Strict and formal SOPs were put into 
place for sample collection and storage.  The study was administered through the NEALS 
Coordinating Center in the same manner as a clinical trial would be run (e.g., the study 
structure, including training, communication, and monitoring, was similar to a clinical trial).  
Materials were managed centrally and shipped to the study sites to reduce variability.  SOPs 
governed the storage of samples, which were stored locally and then batch-shipped to the 
Coordination Center, where they are stored in a central repository.  Quality measures were not 
built into BIO-001, but have been included in subsequent studies. 
 
The contents of the biorepository include almost 16,000 cryovials of plasma; 1200 vials of 














ALS 200 127 78 43 98 115 
UMN/ 
LMN 
49 29 14 10 24 39 
Mimics 105 - - - 43 71 
Healthy 104 - - - 52 52 
 
The study is not complete, as follow-up visits are on-going. 
 
The NEALS Biorepository also includes legacy samples from completed NEALS studies and 
clinical trials that incorporated blood draws for plasma or serum.  There is value to these 
samples, and different tracking mechanisms are used for them.  The SOPs for collecting these 
samples are not standard, but they are recorded. 
 
Clinical data are linked to the samples in the NEALS Biorepository.  Information is collected on 
demographics, concomitant medications, compliance with washout, medical history, and 
disease information for motor neuron patients, including symptom onset date and location, date 
of diagnosis, family history, gene testing history, El Escorial Criteria, and ALSFRS-R.  The 
repository does not include more extensive testing of respiratory function or strength because of 
a trade-off between time and complexity versus a measure of disease progression. 





Regarding identifying and validating biomarkers, Dr. Bowser explained a number of on-going 
efforts using high-scale or high-level approaches looking at specific patterns or signatures within 
plasma or CSF.  Metabolomic studies assess metabolic patterns and signatures within the 
sample.  The medication washout period is important because the high-end approaches can 
identify where samples came from.  NEALS tested a number of tubes from different 
manufacturers to consider the stability of the proteome within samples at given temperatures 
and over time.  The results were built into the NEALS SOPs.  Some of the first metabolic 
signatures were a byproduct of RILUTEK®, so a great deal of work was devoted to the specifics 
of the medication washout and the SOPs.  Other on-going work includes targeted ELISA and 
gel-based techniques to validate protein biomarkers in blood and CSF.  This work also validates 
other published work, and has revealed inconsistencies in published research.  It is important to 
validate discoveries that have been made and published. 
 
The NEALS Biorepository has also been moving in new directions.  New studies include RNA, 
so those samples are being collected.  Targeted analysis considers particular proteins and 
signatures reported in the literature.  Longitudinal studies are also being conducted.  NEALS 
has been engaged in blood-based longitudinal studies and is now looking toward CSF. 
 
To support its goal of sharing samples, NEALS created a Biofluids Repository Committee.  This 
large group of individuals includes representatives from the clinical arena, research, nursing, 
biostatistics, and other areas.  An online application process allows researchers to request 
samples from the biorepository.  Samples and linked clinical information are sent to researchers 
de-identified.  The committee oversees the process and reviews the sample requests.  About 20 
requests for samples have been submitted recently, and most applications have been approved.  
The committee occasionally asks for additional information on the applicant’s assay to 
demonstrate that they can reproduce it.  In many cases, NEALS provides test sets to 
researchers to ensure that the assay is reproducible.  NEALS wants to ensure that the samples 
will yield meaningful data and new information for the field. 
 
The Biorepository is expanding in its centralized form and as a virtual repository.  Samples are 
barcoded, and each site has a barcode reader.  The central site then has access to details 
about each sample and each participant.  New sample types are being collected to respond to 
new approaches in the field.  NEALS serves as a national resource, given that international 
sample sharing is challenging.  Other expansion considerations include longitudinal collection of 
CSF and blood.  Post-mortem tissue is being collected as well, but SOPs and logistics of this 
collection can be challenging.  Potential additional sample types include fibroblasts, saliva, 
urine, and imaging. 
 
NEALS has engaged in a longitudinal biomarker collaboration with 6 sites.  This work utilizes 
the NEALS SOPs, except a medical washout is not included.  Fasting is encouraged, but not 
required.  Atraumatic needles are used to reduce potential side effects.  The virtual repository 
component of the database is being used, and the samples will be available to share with the 
ALS community.  Some of the funding for this project came from NINDS, and requests for the 
samples are being received.  It is important to remember that these samples are being collected 
for the entire community. 
 
  




Department of Veterans Affairs Biorepository:  
Presented on Behalf of the VA ALS Registry 
 
Edward Kasarskis, MD, PhD 
Co-Principal Investigator 
Cynthia Shaw Crispen Chair for ALS Research, Department of Neurology 
University of Kentucky 
Lexington, Kentucky 
 
Dr. Kasarskis indicated that the VA ALS Registry is a longstanding collaborative effort.  Its 
genesis lies in the question of whether military personnel who were deployed to the Persian Gulf 
War I carry an increased risk for ALS compared to military veterans who did not participate in 
the first Persian Gulf War.  The formal study of this phenomenon lasted until 2002 and strictly 
focused on the epidemiological question of whether deployment to the Gulf War theater carried 
an increased risk of ALS.  The publications from this study remain controversial. 
 
Following and overlapping with that study was the VA’s recognition that there may be a more 
significant problem with ALS.  The VA funded the VA registry from January 1, 2003, until 
December 31, 2005.  During the funding period, it was recognized that collecting blood for a 
parallel component would be desirable; thus, the VA ALS Registry DNA Bank was created. 
 
The DNA bank collected DNA samples for the purposes of research on genetic and 
environmental interactions as a genesis of ALS.  The veterans who came forward with 
diagnoses of ALS were not examined by the leaders of the DNA bank.  Instead, a team of 
individuals from the VA ALS Registry examined their medical records to determine diagnostic 
certainty.  The screening questions for the ATSDR registry are based on questions that were 
developed in the context of the VA registry.  The core of cases examined by several 
neurologists formed the gold standard.  Participation in the DNA bank required a separate 
consent form from the registry. 
 
Collecting samples was challenging for a number of reasons.  The individuals lived all across 
the country.  The sample was a prevalence sample, not an incidence sample.  Some 
participants were too ill to travel to their nearest VA location to donate blood for the purposes of 
a DNA bank, so the strategy was to go to them.  A nationwide visiting nurse service was 
contracted by the VA to collect these samples.  The nurses were accustomed to providing 
clinical care, not collecting research samples.  Therefore, they had to be trained to perform a 
different function and to handle samples appropriately.  Contractual logistics were challenging. 
 
All VA ALS Registry participants were asked to participate in the DNA bank via a separate 
consent form, which was mailed to them.  The DNA is saved only for use in ALS studies and 
cannot be shared with researchers who may wish to use the samples as a disease control.  
These limitations were imposed by a variety of organizations that reviewed the consent form. 
 
The effort was successful because samples were collected in individuals’ homes.  Very ill 
individuals were given priority.  The ALSFRS indicated which patients were more advanced, and 
they were reached for samples first.  The logistics for prioritization required an on-going 
dialogue with the nursing service.  The contracted service standardized the training program, 
but because the company’s mission is clinical service provision, they needed to be reminded 
that their function in this case was research-based. 
 
 





The DNA collection proceeded smoothly, in general.  Venous blood samples were desired, and 
the backup sample was buccal scraping cells for people who had poor venous access.  Supply 
kits were provided to the nurses, and samples were shipped to the Boston VA, where the DNA 
was extracted.  The Boston VA is the physical repository for the samples.  The DNA 
Coordinating Center maintains the link between the clinical and genetic data.  The arrangement 
follows VA protocol. 
 
Of the approximately 2000 individuals who were contacted, the vast majority agreed to receive a 
consent form for the DNA Bank via mail (n=1993).  Approximately 1600 consent forms were 
received, and approximately 1200 samples were collected.  Despite the logistical challenges 
associated with collecting samples, the response was very good and is indicative of working 
with a prevalence sample. 
 
The DNA Bank was supported by $2.1 million from 2003 through 2005.  The cost per patient is 
approximately $1400.  Thus far, the primary end user of the bank has been Silke Schmidt, PhD, 
Duke University, for her Genes and Environmental Exposures in Veterans with ALS (GENEVA) 
study.  The VA has imposed restrictions limiting the sharing of DNA samples outside of the VA, 
but those access restrictions have been relaxing so that other researchers may be able to use 
the collection. 
 
Dr. Kasarskis observed that in general, ALS patients want to contribute samples to this effort.  
People who have ALS may not be able to participate in clinical drug studies because of their 
location or because of a lull in the flow of clinical trials, but every ALS patient can participate in 
the DNA Bank.  The VA DNA Bank was built via telephone contact with the veterans, and there 
was a high degree of enthusiasm among participants even without a face-to-face relationship.  
He receives frequent phone calls from patients who want to donate their bodies for research 
purposes.  Financial and logistical support is needed to help them make those contributions. 
 
The bank is a research activity and is funded as such.  There have been attempts to include 
quality-of-life measures from questionnaires completed by clinicians, but those unfunded duties 
have not been successful.  Further, the DNA bank must be user-friendly for patients and 
families, who work extremely hard to meet the physical and emotional needs of ALS patients.  
While the patients may want to contribute, there are limits on what they can do.   
 
Academic recognition for clinicians who assist with the blood samples and who provide the 
phenotypes is important.  The phenotype is critical, and it might be worthwhile to consider an 
online repository to reference the academic contributors to the samples.  These approaches will 
expand the community and build buy-in. 
 
  




Carolinas Neuromuscular / ALS Center Blood Tissue Biorepository 
 
Benjamin Rix Brooks, MD, Director 
Carolinas Neuromuscular/ALS-MDA Center 
Department of Neurology, Carolinas Medical Center 
Adjunct Professor of Neurology, University of North Carolina School of Medicine 
Charlotte, North Carolina 
 
Dr. Brooks explained that the purpose of a biorepository is to collect a plurality of different 
samples that will allow the development of a biomarker.  A biomarker is necessary to identify 
information with regard to diagnosis, rate of progression, or response to treatment. 
 
The Carolinas Neuromuscular / ALS Center Blood Tissue Biorepository collects many of the 
same samples collected by NEALS.  In addition, they collect peripheral blood mononuclear cells 
(PBMCs) that contain lymphocytes and monocytes that may demonstrate different reflections of 
the pathogenesis ongoing in ALS.  Lymphoblasts can indicate different aspects of the pathology 
represented in the peripheral blood compartment.  CSF is important, and in addition, the 
biorepository collects skin and muscle samples from controls looking at genome expression 
data. 
 
Samples are collected under IRB protocols and SOPs that are identical to NEALS.  Clinical data 
are collected via self-report questionnaires that are completed by all participants.  All subjects 
with ALS are characterized clinically in terms of a variety of phenotypes.  Disease controls and 
healthy controls are also included. 
 
A Biological Specimen Inventory system maintains the repository and tracks all samples.  The 
Biological Specimen Inventory system is used for all biological specimens at the Carolinas 
Medical Center and gives staff the ability to track all systems.  Data entry is feature-rich and can 
be completed at locations throughout the Center.  There is a tool for managing requests and 
tracking workflow of samples internally and potentially externally, as well as for tracking 















 Dr. Bouzyk asked for more detail regarding the collection of information, especially 
epidemiological information, about patients who will be included in the biorepository.  The 
ALS Consortium of Epidemiologic Studies (ACES) questionnaire could be a good start to 
collect material and to subset cases for future research not only on demographic 
information, but also on environmental exposure, lifestyle, and other factors. 
 
 Mr. Tison said that the ALS Association has a list of 22 sites for brain and spinal cord banks.  
At least a few of these sites are specifically ALS banks.  He asked whether cooperation or 
replacement, and not competition, should be expected with existing banks and registries. 
 
 Dr. Horton replied that part of ATSDR’s effort includes learning about the registries and 
banks that already exist.  He expressed his hope that their efforts would complement on-
going work in the field and noted that it was too early in the process to think about 
integration. 
 
 Regarding the potential for people with ALS to be included in multiple biorepositories, Dr. 
Sowell suggested adding a module asking if the participants have already participated in a 
biorepository.  Then it might be possible to identify specimens in other biorepositories and to 
create a mechanism for linking data in the registry to specimens that are already in various 
biorepositories.  Further, the approach could help with the problem of de-duplicating 
specimens from the same people that are in various biorepositories.  The community can 
address this issue in a coordinated fashion with the appropriate interactions and data 
collection.  
 
 Dr. Corriveau agreed that people should be asked if they are participating in another bank or 
registry.  Initially, it would be beneficial to acquire DNA from whole blood as well as saliva.  
Genetic material can then verify whether samples are banked in other biorepositories. 
  





 Dr. Brujin added that it is important that the national registry ensure that patients feel that 
they can be part of other, on-going efforts without conflict.  She wondered how to help 
promote the VA registry, as the constraints for using that registry seem to be changing. 
 
 Dr. Kasarskis answered that the changes in the VA registry are dependent on the VA 
approval structure.  When it is appropriate to advertise the registry and to promote the 
mechanism for accessing samples, it will be important to do so. 
 
 Dr. Bowser said that while linking samples in the national bioregistry to samples that have 
already been collected via other mechanisms will present logistical problems, the linking 
should be done.  It is important to demonstrate to patients and the field that the different 
repositories and researchers are working together.  Linking federal information to clinical 
information at sites around the country should be addressed proactively and early in the 
process.  He felt that most people who have been involved in collecting samples would be 
supportive of linking information. 
 
 Dr. Horn said that it will be important to discover duplication, especially in familial cases.  In 
rare diseases, reference and validation populations often overlap, which does not advance 
the science.  The patient community and patient advocacy groups will be important partners 
in building ways to link information.  Regarding the national biorepository, issues of 
governance, sharing, and access are critical issues.  The science of sample collection is 
important, and many great scientists are engaged in that work.  In creating the biorepository, 
they must not forget about the people with ALS who contribute samples, who would be 
disappointed if their contributions were not used by the field. 
 
 Dr. Horton agreed, noting that ATSDR is not conducting its mechanism for using the registry 
for clinical trials in a vacuum.  A panel of internal and external experts is advising them in 
that work, and he envisioned a similar structure for a national biorepository. 
 
 Dr. Berry said that if samples are to be cross-linked, input from a number of IRBs from 
different institutions will be needed.  Different ethics review boards could take different 
viewpoints.  He suggested sampling various IRBs around the country early in the process to 
learn about potential conflicts and differing opinions.  Scientifically, genetically identifying 
samples is a good idea; however, the idea is very complicated from an ethics perspective.  
IRBs may have concerns with identifying samples in de-identified pools of biofluids, linking 
them, and then re-de-identifying them. 
 
 Mr. Tison asked how far 1 blood donation, 1 CSF sample, and 1 skin sample can be spread 
across separate studies over time.  He also asked whether it is realistic for families of 
deceased individuals to want study feedback.  
 
 Dr. Bowser answered that in the case of blood and CSF, a few milliliters of fluid are 
collected.  Those samples are split into different tubes with various amounts of fluids.  A 
study could use 1 of those tubes, so a patient could provide sufficient material for anywhere 
from 10 to a few dozen studies.  DNA and postmortem tissue are relatively stable and can 
be stored and used for some time; however, depending on the type of analysis, biofluids 
have a lifetime.  He preferred an approach that ensures that fluid samples are used while 
they are viable, and stressed that allowing access to samples for studies is important. 
 




 Dr. Cross added that the use of samples also depends on the data sharing agreement of the 
institution.  For instance, her repository requires that all data from a sample is shared with 
the repository for use in other studies. 
 
 Dr. Berry said that fibroblasts from skin biopsies can be used indefinitely, and is important 
that the consent process makes that clear.  Regarding sharing information with patients and 
families, he said that banks are usually built in a de-identified way.  It is therefore difficult to 
link specific samples to specific results.  At the same time, results from samples from the 
bank can be tracked so that patients and families can understand the importance of what 
the bank is accomplishing. 
 
 Dr. Brady added that brain banks can give specific feedback by providing neuropathology 
reports to participating families.  His brain bank also provides consultation with a 
neuropathologist to explain the report.  Newsletters and websites are general ways to share 
information with patients as well.  He noted that well-written and broadly-conceived consent 
forms are a crucial piece of their work. 
 
 Dr. Kasarskis added that IRB consent can be a significant issue, especially when working 
with multiple institutions.  If institutional buy-in is present, then a centralized IRB could be 
used for the purposes of contributing to a national effort such as the biorepository.  The 
Neuro Next Clinical Trial Network applications require institutional agreement to use a 
centralized IRB.  Institutions may need to be educated about this approach. 
 
 Dr. Corriveau said that cross-disease relevance has been important for ALS research, and 






Marshfield Clinic Biobank 
 
Catherine McCarty, PhD, MPH 
Principal Research Scientist 
Essentia Institute of Rural Health 
Duluth, Minnesota 
 
Dr. McCarty shared her experience with the Personalized Medicine Research Project (PMRP) at 
the Marshfield Clinic in Marshfield, Wisconsin.  The ultimate goal of the PMRP was to collect 
information to truly personalize healthcare in the long-term.  Its short-term goal was to establish 
one of the first population-based biobanks in the US to conduct research in genetic 
epidemiology, pharmacogenetics, and population genetics.  The bank includes samples from 
20,000 individuals and is part of the Electronic Medical Records and Genomics (eMERGE) 
Network, funded by the National Human Genome Research Institute (NHGRI). 
 
Marshfield is a town of 20,000 located in the center of Wisconsin.  The Marshfield Clinic is a 
large healthcare system.  The Marshfield Epidemiologic Study Area (MESA) is centered in 
Marshfield.  Periodic validation studies have shown that nearly everyone in MESA seeks all of 
their healthcare through the Marshfield Clinic, and a shared electronic health record system with 
the hospital captures inpatient and outpatient information.  Several generations are represented 
in the biobank.  The system of care includes all specialties and subspecialties, save whole 
Lessons Learned from Biorepositories 
 




organ transplant, and has had internally-developed electronic health records since the late 
1960’s.  A research foundation has strong programs in genomics and clinical research.  More 
than half of the Marshfield population, and about two-thirds of the Medicare-age population, 
belong to the health maintenance organization (HMO), allowing for capture of health events that 
occur outside the system. 
 
Creating the biobank required a great deal of consultation and education at multiple levels.  The 
consultation and education process included a Community Advisory Group (CAG), a Scientific 
Advisory Board (SAB); an Ethics and Security Advisory Board (ESAB); focus group discussions; 
community talks; media releases; a health message video for waiting rooms; and an employee 
newsletter.  Planning began in 2001, and recruitment began in September of 2002.  The focus 
group process included opportunities for commentary on the materials and for feedback on the 
large-scale DNA biobank.  Separate focus groups were created for employees.  Half of the 
working-age adults in Marshfield are employed by the clinic or the hospital.  Overarching 
themes that emerged from the focus groups included the following: 
 
 Trust in the Marshfield Clinic 
 Opposition to human cloning, which was an issue in the lay press at the time 
 Concern about insurance discrimination, especially given the Marshfield Clinic-owned 
insurance company 
 Confidentiality of data, particularly clinical data (employees were especially concerned about 
this) 
 Some would never participate regardless 
 
The focus groups recommended clarifying data security procedures and keeping the materials 
very simple.  The biobank’s security provisions included one-way data encryption and a number 
of physical and non-physical security measures.  The eMERGE network focuses on data 
security and on the level of data that is shared with the smallest risk of re-identification; 
however, the most significant risk for re-identification is internal.  Every healthcare system 
conducts regular audits to determine who is looking at medical records.  Under the Marshfield 
policy, anyone with access to the medical record could not have access to the linked genotypic 
and phenotypic data.  Wisconsin also had strict data confidentiality laws in place.  The project 
also obtained a Certificate of Confidentiality from NIH. 
 
More focus groups were conducted in 2003, after recruitment for PMRP had been on-going for 
about 1.5 years.  It was important to assure the IRB that the groups were not intended to recruit 
for participation in the biobank.  The focus groups addressed non-participants in the biobank.  
The main reason given for non-participation was a lack of interest.  Two primary concerns 
emerged from those groups, 1) the materials for the biobank were dense and discouraged 
people from participating; and 2) confidentiality concerns, especially from employees. 
Additionally, some people were not aware of PMRP.  The groups suggested making the 
materials more concise and offering more financial incentives to participate.  The participants 
were compensated $20 for their time.  PRMP responded by creating simple newspaper inserts 
and posters with information about the program, with input from the CAG. 
 
The CAG includes 20 members who represent a cross-section of the community.  They meet 
about 3 times a year to provide feedback on all aspects of PMRP, such as protocol changes 
and newsletter content.  Early in the process, when NHGRI had provided funding for 
participation in the eMERGE network and the Database of Genotypes and Phenotypes 
(dbGAP), a broad consent form was needed to allow for the sharing; however, dbGAP did not 
exist when the PRMP consent form was created.  The CAG expressed initial hesitation because 




the government would be responsible for keeping the data confidential, but overwhelmingly, the 
group supported sharing the data.  They suggested creating a newsletter article on the subject 
and asking for response.  The newsletter is sent 3 times a year to about 12,000 homes.  Only 1 
person did not want to be included in dbGAP and withdrew from the project.  That response 
validated the decision not to re-consent all participants in the project, so a waiver of informed 
consent was obtained through their IRB. 
 
CAG discussed stored pathology samples as well.  When there is broad consent to access the 
medical record, the access does not extend to stored pathology samples unless specifically 
stated.  Access is available to the pathologist’s interpretation of those samples.  PMRP could 
either apply for a waiver of informed consent or re-consent the 20,000 participants.  The CAG 
was initially surprised that the samples were saved for so long, and expressed a desire to have 
those samples used for good science.  The group recommended against committing time and 
financial resources to the re-consent process.  The information was shared in the newsletter, 
and the response to the newsletter was positive.  A waiver of informed consent was obtained. 
 
A joint meeting was held with the CAG and the ESAB.  The meeting focused on the issue of 
access to prospective residual clinical blood samples, especially for sequential samples of 
serum and plasma.  The initial consent form did not address this issue.  The CAG was 
supportive, and the ESAB was concerned and felt that re-consent was necessary.  Another 
newsletter article was generated, and the group also suggested sending a specific letter to 
participants about the protocol changes and ongoing studies.  A small percentage of 
participants elected to withdraw from the study for various reasons. 
 
The study logistics included active recruitment and consent of MESA residents aged 18 and 
over.  The newsletter includes a letter of introduction and a reminder to have blood drawn.  The 
reimbursement includes $20, and an additional $10 for an extensive dietary history 
questionnaire and Baecke physical activity questionnaire. 
 
The process for accessing biobanks should not be tedious.  An initial feasibility request is made, 
and the project undergoes scientific merit review, either through a funding agency or internally 
at the Marshfield Clinic.  IRB approval is obtained for all studies.  An Oversight Committee 
reviews the project as well, as the biobank is a relatively limited resource.  Funding is required 
for phenotyping and identification and retrieval of samples.  Phenotypic and genotypic data are 
returned to the PMRP within 6 months after completing analyses. 
 
Approximately 20,000 people are currently enrolled in the PMRP, aged 18 through 102; 57% of 
participants are female, and 98% are European-American.  The biobank includes DNA, plasma 
and serum samples as well as information on dietary intake and physical activity.  Participants 
have consented to allow sharing of de-identified data and samples.  There is access to the 
extensive Marshfield Clinic Electronic Health Record.  The project has the ability to re-contact 
subjects.  Genome-Wide Association Studies (GWAS) data are included for approximately 5000 
subjects, and a molecular fingerprint project has been conducted for all subjects.  Whole 
genome sequencing has been completed for 24 subjects. 
 
  




Lessons learned from the PRMP include the following: 
 
 Multidisciplinary collaborations are key. 
 Informatics research and support is critical and must keep pace with genetic technology for 
discovery and translation. 
 On-going community consultation at all levels is vital. 
 Regular direct contact with all subjects should be planned. 
 It is more efficient to collect information up-front rather than to reach participants after they 
have enrolled. 
 Process samples under Clinical Laboratory Improvement Amendments (CLIA), which is 
important for returning results and using the samples for healthcare purposes. 
 
Information about the project, including consent forms and ongoing projects, is available at 
www.mfldclin.edu/pmrp.  
 
Genetic Alliance Biobank 
 
Liz Horn, PhD, MBI, Director 
Genetic Alliance Registry and BioBank 
Washington, DC 
 
Dr. Horn commented on how technology, informatics, and other advances and factors have 
changed the landscape of research.  The single-condition, siloed collections of the past will not 
advance science.  Cross-disease, multi-condition collections are needed.  It is important to have 
shared infrastructure, group governance, and protocols for standardized data.  Further, data are 
needed from multiple sources.  A relatively new phenomenon is the emergence of the “citizen 
scientist” movement, with dynamic involvement of consumers, advocates, and citizen scientist.  
Technology drives this movement, and there are many opportunities.  In the past, drug 
development progressed in a linear fashion.  Today, translational science operates like a 
network.  Registries and biobanks are critical to advancing science.  Despite challenges in 
funding and other areas, great opportunities exist for sharing and collaboration. 
 
The Genetic Alliance Registry and BioBank (GARB) was created in 2003 with the goal to 
provide a mechanism to collect well-characterized and well-annotated biospecimens with the 
necessary clinical data.  This work is conducted in the realm of rare diseases.  It is challenging 
to find participants, and scientists are located in different places.  Sharing can be limited.  GARB 
created an infrastructure and logistics to collect data and biospecimens and to secure research 
collaborations, assemble cohorts, and provide expertise.  Different advocacy groups administer 
registries and biobanks through the system.  In this model, the groups own, govern, and 
steward their own samples.  Often, staff scientists and members of academic collaborate with 
the groups. 
 
Specimen collection for the biorepository, which mainly consists of blood collection for DNA, is 
logistically straightforward.  Tissue collection can be more complicated.  The system includes 
different mechanisms for donation, as different groups need different materials.  The system 
operates as a “research institute without walls,” providing opportunities to collect samples and 
data, including provider-entered data and patient-entered data.  The cost of provider-entered 
data can be a challenge.  GARB has its own IRB and broad consent forms with the ability to re-
contact participants.  Participants can agree to share samples only for their condition, other 
related conditions, or broad conditions.  Prioritization of samples is important, particularly in rare 
samples.  Participants are active.  The GARB model is unique because it is able to be nimble 




and to address the needs of different groups and their research interests.  Flexibility is an 
important part of the approach. 
 
When building a biobank, considerations of collection, processing and storage, and access are 
important.  It is also important to think early in the process about how the samples will be used. 
 
Collection considerations include: 
 
 Types of samples needed 
 Kinds of donors needed, and inclusion and exclusion criteria 
 Timing of the collection, which can be critical at the point of care 
 Where samples will be collected 
 When will samples be collected 
 Who will collect the samples 
 How often will samples be collected 
 Whether other similar sample collections exist, and how samples can be shared 
 
Processing and storage considerations include: 
 
 Where samples will be processed 
 How samples will be processed 
 Where samples will be stored 
 How samples will be accessed 
 Types of experiments samples will be used for 
 SOPs for extraction for storage 
 
Access considerations include: 
 
 Who has access to the samples 
 Who determines access to the samples 
 What the protocols will be (Through the Alliance’s IRB protocol, all data are de-identified.  
The patient advocacy group that serves as the steward of the data has the opportunity to 
recontact as needed) 
 What the protocols are for distribution 
 What the governance mechanism will be 
 How results will be returned, at least aggregate results 
 How will samples be used 
 
GARB created a criteria and scoring scheme for vendor assessment.  They conduct frequent 
evaluations of registries and biorepositories, and they have moved their biobank multiple times.  
The scheme assigns points to scalability and clinical data, which is sometimes more important 
than the biospecimen.  Data standards and linkage, as well as the samples and quality control, 
are assessed in the scheme.  Very few vendors have both registries and biobanks, and it is 
important to link data to samples.  The following toolbox is helpful in starting a registry or 
biobank: 
 







GARB generated a Webinar on demystifying the IRB as well as other tools and tips, including a 
startup guide of 53 questions. 
 
Dr. Horn shared the following lessons that GARB has learned: 
 
 Do not duplicate efforts, especially given that biobanks are expensive and administratively 
burdensome. 
 Develop partnerships to share data and resources where possible. 
 Ensure that the biobank is sustainable over time. 
 Use common data fields and controlled vocabulary to allow comparison with multiple data 
sets. 
 Follow best practices. 
 Retention is critical, because it is harder to recruit new participants than to keep those that 
are participating. 
 Prior proper planning prevents poor performance. 
 Stewardship is vital. 
 Good partners are essential. 
 People matter. 
 Involve advocacy organizations and the community. 
 
Advocacy organizations understand the unmet needs of the community and can develop trust 
within the community.  They can leverage scarce resources and facilitate collaboration between 
stakeholders.  Community members and advocacy groups are committed to the cause and 




 Dr. Bouzyk commented on the regulatory aspects of the biobanks, which will be important in 
the future. 
 
 Dr. Boylan said that his institution’s IRB has permitted his team to provide DNA test results 
to patients who contributed DNA in a research study.  Those collections were not conducted 
in a CLIA facility.  This work raises the issue of what constitutes healthcare, and what 




constitutes information.  Patients who are not necessarily being treated or managed are 
made aware of the results of the research, and they tend to be appreciative of the 
information.  A staged process gives patients an opportunity to agree to receiving the 
information, and if interest is not expressed at the point of collection, then the information is 
not offered.  More commonly, the patients ask for follow-up information and genetic 
counseling, when appropriate. 
 
 Dr. Bowser said that collecting samples for research purposes as opposed to diagnosis may 
preclude using a CLIA setting.  He asked Dr. McCarty about the letters that were sent to 
participants regarding participating in ongoing studies.  Few participants opted out of the 
project, and he asked how it was ensured that the participants read and received the letter. 
 
 Dr. McCarty answered that the ESAB discussed whether a response would be required.  A 
stamped, addressed postcard was included with the letter to facilitate response, but there is 
no guarantee that the letter was read. 
 
 Ms. Bledsoe asked about the types of research data have been received by PMRP and how 
the varying formats and documentation of research protocols were handled. 
 
 Dr. McCarty responded that external collaborators do have access to de-identified 
phenotypic data, which comes from the electronic medical record and is processed internally 
and well-documented.  They do not have direct access to the electronic medical record. 
External investigators share genotyping data, which comes from different platforms.  The 
bioinformatics group developed a template for how that information is documented. 
 
 Dr. Cross added that questionnaires as well as serum and plasma data could also be 
received.  The serum and plasma data are documented according to its platform and the 
testing that was conducted. 
 
 Dr. Corriveau asked how many full-time employees (FTEs) are associated with the PMRP.  
Data sharing in the proposed national biorepository will take a different form from the 
contact conducted by the PMRP. 
 
 Dr. McCarty answered that the initial recruitment into the project included 2.5 FTEs in the 
laboratory, 10 FTE research coordinators, and 1 part-time genetic counselor.  Their 





Scott Hixon  




Mr. Hixon explained that Fisher BioServices is one of the world’s largest biorepositories.  They 
manage a number of commercial and governmental biorepositories.  Many biorepositories 
began in single labs and the samples may not have been monitored properly.  The inventory 
system may be inadequate, and samples may be improperly labeled.  Frequently, access to 
samples was not controlled.  Emergency procedures may not be in place, and back-up power 
Technology for Sample Collection and Processing 
 




may not be available.  Fisher is often contacted by these small biorepositories after a freezer 
has malfunctioned, and the infrastructure is not present to support the biorepository. 
 
Mr. Hixon reviewed the “basics” of biorepositories, pointing out that redundancy is needed in 
freezer and refrigerator storage space and emergency back-up power.  Service plans or on-site 
engineering should be in place.  Equipment should be validated and serviced on a regular basis. 
An inventory system for sample management should be able to support the project, and if the 
work has clinical implications, then the system must be compliant with Title 21 of the Code of 
Federal Regulations (CFR).  The inventory management system should allow on-line sample 
request and destruction.  The facility should have security measures to include 24-hour-a-day, 
7-day-a-week monitoring.  The repository should have an escort policy.  Back-up storage 
capacity should be available for all temperature ranges.  Temperature should be monitored at all 
times.  Data should be collected at least once per day, and an electronic data system can 
collect continuous alarms. 
 
There are many different types of repositories in the US.  Private repositories are built for 
internal use and for the company’s internal needs, such as a pharmaceutical company.  Some 
commercial biorepositories are created for local communities, while others have an international 
presence with multiple locations.  Different inventory systems are used by commercial 
biorepositories, and they should be capable of integration with other systems.  Commercial 
repositories tend to be more flexible than other types, and they have a wide range of storage 
capabilities.  Some commercial biorepositories have complementary services such as 
laboratory, kitting, storage, distribution capabilities, clinical trial support, direct billing to 
investigators, and drug packaging.  Some commercial biorepositories are self-supporting.  
Examples of government repositories include the National Cancer Institute (NCI) Clinical 
Repository in Frederick, Maryland; and repositories maintained by the Women’s Health Initiative 
(WHI) and the National Children’s Study (NCS).  Government repositories may or may not be 
open for other uses. 
 
Repositories in the future will likely be fully automated.  There are limitations to using an 
automated system, as systems are limited in certain conditions such as liquid nitrogen and -81s.  
So far, the automated systems only handle liquid samples.  Future repositories are likely to 
utilize automated processing.  These processes can sometimes be integrated with samples for 
biorepositories.  Manual interaction is still required for some processes. 
 
Storing samples is only half the battle.  Collecting, transporting, and processing samples is just 
as important to the long-term success of a repository.  The design of the repository should 
consider what will be collected and what the downstream applications of the samples will be.  
Understanding the study will have an impact on how samples are collected, such as central 
versus random collection; one-time versus multiple collections per subject; and local, central, or 
multiple site processing.  Other considerations include how data will be connected to the 
sample, and labeling samples correctly. 
 
Collection inconsistencies can be avoided by providing standardized collection kits, especially if 
collection will take place at participants’ homes.  The kits should include all supplies for 
collection and shipping.  Collection forms or electronic data capture can be used.  Electronic 
data capture is easier at a collection site, as opposed to at a participant’s home.  The collection 
kits should include pre-labeled tubes, containers, forms, and well-written collection procedures. 
 
  




The physical collection is more likely to be successful if the kit includes detailed instructions.  
Samples should be collected in a specific order.  A butterfly apparatus is used to collect 
samples with liquid preservatives, and the patient’s positioning is important.  The collection form 
should be completed as soon as the samples are collected.  The form can double as a shipping 
manifest, and it should be pre-labeled and specific to the kit. 
 
Collection kits should be designed to support the project correctly.  Patient specific-kits could be 
used to link data in advance, or kits could be linked at a later time.  Stock kits can also be used, 
or “just in time” kits can be created at the time that it is requested.  Kits should have the 
flexibility for large or small projects.  Because the samples will be collected at participants’ 
homes, some of the processing cannot occur at the site.  The samples must be sent to a central 
processing facility, and this approach limits the types of samples that can be collected.  
Shipping supplies and instructions should be included, and air bills should be pre-filled. 
 
A number of processes can be applied to the samples, including blood fractionation and 
aliquotting.  If buccal cell or saliva samples are obtained, then limited processing is required.  
DNA and RNA samples can be processed when the sample is received, or samples can be 
stored and processed later.  Unless they are going to be stored, samples should be processed 
on the day they are received by the laboratory.  After processing, the samples should be placed 
in permanent storage.  The inventory should be updated, and online access is important.  Data 





 Dr. Brooks asked about data on failure and whether samples were lost. 
 
 Mr. Hixon answered that Fisher has data on how long their generators have had to run.  
They have operated for 48 hours.  Samples can be monitored, and thus far, no samples 
have been lost.  Freezers do fail, and mechanical freezers are more apt to fail than liquid 
nitrogen freezers. 
 
 Dr. Horn said that GARB uses a commercial repository vendor because of the important 
logistics associated with collection and storage.  She noted that when kits are shipped to 
participants’ homes, a contact person should be available to answer any questions that 
participants might have. 
 
 Mr. Hixon agreed, noting that depending on the nature of the study, repository staff can 
serve as a point of contact, or the sponsor of the study can fill that role.  Dr. Horn added that 
the protocol includes a chain of command. 
 
 Dr. Horton commented that it has not yet been decided whether mail-out kits would be used 
for the National ALS Registry Biorepository.  They are exploring all options. 
 
 Dr. Corriveau asked about samples that would be suitable for collection at home, other than 
buccal swabs. 
 
 Mr. Hixon replied that blood samples can be collected, but they should be sent back the 
same day that they are collected.  It is important that at-home collection should be as easy 
as possible for the participants.  For instance, all samples should be sent at the same 




temperature.  Fisher participates in studies that are nurse-based, in which participants draw 
their own blood, and other studies include on-site phlebotomy services at homes. 
 
 Dr. Horn added that her group has conducted outreach events with an on-site phlebotomist 
and has sent a phlebotomist to a participant’s home. 
 
 Dr. Horton asked whether finger-pricking kits could be used.  Mr. Hixon said that Fisher does 
not usually provide finger-pricking kits, as larger volumes of are usually needed.  Dr. Sowell 
noted that in order to be successful, a blood spot needs to be collected properly by a trained 
person. 
 
 Dr. Bouzyk asked whether Fisher has conducted research into evidence-based biobanking.  
Mr. Hixon said that Fisher does not conduct research, but they partner with others to do that 
work. 
 
 Dr. Vaught reported that the Office of Biorepositories and Biospecimen Research at NCI 
funds biospecimen research into methodologies and evidence-based practices.  They hold 
an annual symposium on these issues and they fund contractors to conduct studies for 
evidence on how to best collect, process, store, and disseminate samples.  Much of the 
work has not been published or widely disseminated. 
 






Marta Gwinn, MD, MPH 
Senior Consultant for Epidemiology  
McKing Consulting Corporation 
Centers for Disease Control and Prevention 
 
Dr. Gwinn reminded the group that the meeting’s goal was for the expert panel to provide input 
into the draft biorepository protocol and to provide advice on key aspects of the protocol, such 
as the types of samples to be collected and the sample size.  Although their focus should not be 
on logistics, it is impossible to completely separate logistics from scientific objectives. 
 
The goals of the National ALS Registry Biorepository Pilot Study are to maximize the potential 
utility of the samples that are collected for scientific research, given registry parameters.  This 
project is being constructed within the context of the existing registry program.  The pilot study 
should maximize cost-efficiency, which is crucial to the sustainability of the project.  The pilot 
study will make recommendations for long-term sustainability and will recommend a process for 
providing research access. 
 
No single study or database can provide all the answers about ALS, even basic data such as 
how many people have ALS, or the underlying genetic and environmental causes of the 
disease.  Other questions pertain to how understanding those causes can lead to prevention 
and treatment, and the biomarkers that are useful for predicting disease progression and 
treatment response.  An integrated approach is needed to answer all of these questions, 
bringing together findings from epidemiologic, clinical, and basic research. 
 
Presentation of the Biorepository Protocol 
 




The National ALS Registry Biorepository could add to on-going efforts.  The project presents the 
opportunity to correlate biomarkers with the extensive epidemiologic data that are collected with 
the registry.  The project also presents an opportunity to enroll a nationally representative, 
population-based sample of people with ALS.  The sample will not be selected by geographic 
area, exposure, or clinical characteristics.  The biorepository could add to the total number of 
biological specimens available for research on ALS. 
 
Dr. Gwinn presented classes of environmental factors that have been proposed for studies of 
ALS susceptibility: 
 
Proposed Risk Factor Example / Potential Biomarkers 
Infectious agents  enterovirus 
PCR for enterovirus RNA in CSF, brain or spinal cord 
Pesticides     organophosphates 
paraoxonase enzyme activity, PON1 genotype (blood) 
Metals     lead, mercury 
brain, blood, CSF levels of metals and organic compounds 
Drugs, chemicals formaldehyde 
cytogenetic biomarkers 
Injury    head trauma 
A-beta protein deposition in neurons, APOE genotype 
 
New research findings in the genetics of ALS have changed the way the field thinks about the 
disease.  These breakthroughs have been possible because it is relatively easy to study genetic 
variation in relation to health outcomes. 
 
Dr. Gwinn presented a table based on a recent article that described a “roadmap” for 
biomarkers in ALS research.  Skin and muscle samples are not included on the table because 
the Bioregistry proposes to collect samples from participants outside the clinical environment.  
CSF will not be collected onsite.  Each sample has comparative logistical and scientific 
advantages and disadvantages.  Some samples are uniquely valuable for certain purposes.  It is 
important to create a proposal that balances the types of samples with the types of anticipated 
analyses.  The panel should discuss the relative merit of these samples. 
 
Characteristic Blood* CSF Urine Saliva 
Proximity to CNS pathology ++ +++ + + 
Less molecular complexity + + ++ +++ 
Less invasive ++ + +++ +++ 
Practicality of sampling +++ ++ +++ ++ 
Ease of handling for storage ++ + ++ + 
Resistance to exogenous drug contamination + +++ + ++ 
Candidate molecules to date ++ +++ + + 
Potential for DNA/RNA analysis +++ + + ++ 
+++ strong; ++ moderate; + weak 
*Plasma versus serum needs to be specified; serum may have advantages for the stability of some proteins, e.g. 
immunoglobulins. EDTA sample will be needed for DNA or RNA studies.  
 




Dr. Gwinn shared a proposed minimum specimen collection, and noted the potential for self-
collected specimens.  Some collected specimens could be desirable for certain analyses and as 






ml Fractions Examples of potential analyses 
Blood 




DNA, proteins, red cell lipids  
   2 Clot activator 8 Serum  
Clinical biochemistries, metabolic products, 
other small molecules 
   3 
Acid citrate 
dextrose 
6   DNA, RNA, immortalized lymphocytes 
Urine 9 -- 
Electrolytes, environmental chemicals, 
metabolic products, gut microbiome 
Potential self-collected specimens 
Saliva 2 -- DNA, others? 
Urine 9 -- 
Electrolytes, environmental chemicals, 
metabolic products 
Nail clippings -- -- Metals 
Hair clippings -- -- Metals 
 
The main goal of the pilot project is to develop the National ALS Registry Biorepository as a 
research resource.  The priorities are to collect biospecimens that complement the types of data 
that are in the registry.  For example, the registry does not include imaging data, but does 
include occupational and environmental data.  The pilot project should allow for comparisons or 
combinations with other studies in order to maximize scientific utility.  The collection should be 
“future proofed” as much as possible to anticipate technologies or research priorities that could 





VA Cooperative Studies Program VA Biorepository Brain Bank (CSP501) 
 
Christopher "Kit" Brady, PhD 
Director, Scientific Operations 
VA Biorepository (151C), VA Boston Healthcare System 
U.S. Department of Veterans Affairs 
Boston, Massachusetts 
 
Dr. Brady described his experience with the VA Biorepository (VAB) Brain Bank, a national ALS 
brain bank.  He reminded everyone that the VA became involved with ALS and brain banking 
because ALS has been linked to deployment to the Persian Gulf and military service in general. 
In 2006, the Scientific Advisory Committee of the VA ALS Registry requested that the VAB Brain 
Bank be initiated by the VA Cooperative Studies Program to collect brain and spinal cord tissue 
from Veterans in the ALS registry.  The VAB ALS Brain Bank (CSP 501) is coordinated at the 
Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) at the 
Boston VA.  MAVERIC is responsible for enrollment and patient follow-up, as well as 
Presentation of Brain Bank Protocol 
 




coordination of tissue recovery throughout the US.  Tissue samples are shipped to the Southern 
Arizona Core Tissue Laboratory (SACTL) in Tucson, Arizona.  Diagnostic neuropathological 
analyses are conducted at the VAs in Bedford and Boston, MA.  Those reports are made 
available to patients who are interested in receiving it. 
 
The brain bank received names from the VA ALS Registry and contacted participants during the 
time that the registry was open.  Subsequently, the brain bank has developed a new initiative 
with the Boston VA neurology department and has started to work with other VA neurology 
departments across the country.  Enrollment begins with a description of the study on the 
telephone.  Interested patients are mailed a consent form, which is reviewed over the phone.  
The patients and next-of-kin sign the form, and next-of-kin buy-in from the beginning of the 
process is very important.  When the consent form is received, medical history is collected, 
including a baseline ALSFRS.  The ALSFRS is administered semiannually in order to collect 
longitudinal ALSFRS data.  Frequency of follow-up calls are scheduled depending on the 
severity of the disease state, with more frequent calls given to those with advanced ALS. 
 
Tissue recovery is critical.  Each enrolled patient is connected to their local VA.  If the VA is not 
able to conduct the recovery, then the brain bank contracts with the local medical examiner’s 
office or diener service.  Those contracts are important to have in place, as recoveries may be 
conducted after-hours or on weekends, when VA pathology departments are closed.  Another 
important partner in the process is the family’s funeral home in order to coordinate 
transportation.  The brain bank also pre-positions boxes and has the goal of receiving the boxes 
in less than 24 hours. 
 
Persons with ALS and their families are extremely invested in the process.  Of the VA ALS 
Registry participants who were contacted, 232 patients, or 55%, agreed to participate in the 
brain bank.  Of those who agreed, 142 are undergoing regular follow-up and data collection.  Of 
the 90 participants who have died, tissue has been successfully recovered from 84 patients.  
The losses were due to pager failure or due to family members changing their mind about 
participation at the time of death.  Participants have been consented in 47 states, and the brain 
bank has developed a national network of VA hospitals, diener services, and medical examiners 
to perform tissue recoveries. 
 
The bank in Tucson operates under standard brain banking procedures with respect to 
specimen grossing, digital imaging, quality control, storage of samples, and software 
development.  The neuropathology report is prepared by the staff at the Tucson and Boston.  
The Tucson bank oversees tissue distribution.  The Tucson site also collects and stores control 
samples, and it is important to think about how to collect and store a national sample of controls. 
 
Different brain banks and biorepositories use different software.  The VAB Brain Bank uses 
Tissue Metrix Biospecimen Management Software.  It is important to consider whether different 
types of software are compatible and whether data from one can go into another.  Tissue Metrix 
allows for tracking events about samples, including data from the donor, results of grossing, 
results of diagnostic neuropathology, collection, gross digital images, the sample location, 
tracking sample distribution, and feedback from end users. 
 
Clinical data collection is critical to the usefulness of the samples.  The VAB Brain Bank has 
access to pre-existing clinical data from the VA ALS Registry.  The brain bank also continues to 
collect longitudinal data, including updating medications, disease progression, and the VA 
electronic medical records. 
 




Tissue distribution is currently conducted via a paper-based process.  Requests are reviewed 
for feasibility, approval, and funding.  The VA Central Office assembles a review committee to 
consider the request and makes final determinations regarding who gets tissue, and how much 
tissue is released.  Tissue and clinical data are then released as needed by the investigator. 
 
Informed consent is important, given that the tissue can only be used as the donors consented it 
to be used.  The process should be broad-based and should allow for on-going collection and 
re-contact.  Levels of consent are extremely important.  In addition to the person with ALS, 
participation and involvement from the next-of-kin is critical to the success of the work.  Consent 
with the next-of-kin is reconfirmed at death, and establishing understanding early in the process 
creates low levels of distress.  Consent should be clear regarding disclosure, confidentiality, and 
Genetic Information Nondiscrimination Act (GINA) language.  A Certificate of Confidentiality 
from NIH adds additional confidentiality protection to the process. 
 
Other critical elements of the brain bank include informatics and data capture, which will help 
ensure that the tissue is useful in the future.  Tissue processing expertise, infrastructure and 
data management, governance, and distribution are other issues that must be considered.  The 
cost of administering a brain bank is significant. 
 
For the proposed pilot study, Dr. Brady suggested utilizing one of the brain banks in Boston, 
Massachusetts rather than the Tucson bank.  The Boston bank is serving as the brain bank for 
ALS, Alzheimer’s Disease, and a number of other diseases, conditions, and initiatives.  This 
pre-existing infrastructure has a history of collecting both veteran and non-veteran tissue 
samples.  Using this bank would also ensure that the VA bank and the ATSDR bank would use 
identical procedures, measures, and structures.  ALS brains are a precious resource, and 
distributing those resources across banks would protect them against complete loss in case of 
failure.  Utilizing pre-existing infrastructure and expertise would also reduce start-up costs.  Dr. 
Brady acknowledged the VAB Brain Bank staff, which focuses on personal contact with 




 Dr. Belay asked about reimbursement for conducting autopsies.  The system for 
neurodegenerative disease charges $3000 to $5000, but other issues are associated with 
that work, such as infection control.  Dr. Brady replied that most of the time, the VA 
departments will complete the autopsy at no cost.  The average fee for other services is 
approximately $1000. 
 
 Dr. Bradley commended Dr. Brady on the national network of dieners, funeral homes, and 
pathology departments.  That network is key to the effort, as collections occur at any time of 
the day or night.  He asked whether samples are still being collected and whether VA 
funding for the collection is ongoing.  He also asked about the population of the US that is 
covered by veterans and the capacity for expanding to the general population, given that 
veterans constitute 10% of the population, and there are approximately 10,000 cases of ALS 
per year in the general population. 
 
 Dr. Brady replied that the VA funds the brain bank on a year-to-year basis, and the VA has 
been generous and supportive in funding and providing for the project.  





 Regarding veterans and the general population, Dr. Kasarskis said that they could acquire 
that data.  He noted that autopsies are “a lost art” and that autopsy rates are currently low 
(e.g., performed on only 1% to 3% of deaths).  Engaging the family in the process is 
extremely important, given that the donor’s survivors ultimately make decisions and give 
legal permission to pathology departments to acquire the tissues.  It is important that the 
process is very simple for the legal next-of-kin, especially given that the legal next-of-kin 
could be, for instance, an estranged spouse who may not have been involved in the initial 
discussions. 
 
 Dr. Brujin asked how many requests for tissue have been received, and how many have 
been granted.  Dr. Brady replied that the brain bank has released 4 samples, and 12-16 
requests have been made.  Some requests are still under review. 
 
 Dr. Brujin asked how the availability of the bank is disseminated and promoted.  Dr. Brady 
answered that the review and request process had been burdensome in the past, but was 
now resolved.  They are revisiting their procedures based on early experience with releasing 
tissue and will make a large-scale announcement about the availability of tissue. 
 
 Ms. Bledsoe added that the process is being streamlined in order to facilitate access to the 
specimens. 
 
 Dr. Gubitz asked whether samples were available only to VA researchers.  Dr. Brady replied 
that the tissues are released to VA and non-VA researchers.  The Technical Director of the 





Wendy Kaye, PhD 
Senior Epidemiologist 
McKing Consulting Corporation 
National ALS Registry Program 
Agency for Toxic Substances & Disease Registry 
 
Dr. Kaye opened the floor for suggestions regarding any of the discussion topics and subjects 
that had been introduced.  She emphasized that they were hoping for suggestions pertaining to: 
 
 The number of specimens that might be reasonable for a feasibility study 
 What, if any, additional data should be collected along with the specimens or in addition to 
specimens 
 What specimens should be collected 
 The potential for self-collection option and long-term implementation 
 Brain banking 
 Collection of tissue samples 
 
  
Discussion of ALS Biorepository and Brain Banking Protocol 
 






 Dr. Brooks suggested that one of the principles of the biorepository might be to bring 
existing repositories together.  The biorepository could have a component of new specimens 
as well as a component of curating the existing specimens. 
 
 Dr. Kaye agreed that collaboration between existing resources and documentation of 
retrieving samples from more than one resource for a project should be pursued, but not as 
part of this endeavor, which was to collect new specimens attached to the National ALS 
Registry.   
 
 Dr. Brooks agreed, but noted that the protocol should address potential issues associated 
with persons contributing to more than one repository.  Dr. Kaye said that the specimens 
can be “fingerprinted” and de-identified, and it will be possible to determine whether they are 
in multiple registries. 
 
 Dr. Corriveau said that the NINDS Repository checks a set of 6 marker satellites of DNA for 
every sample to make sure that when 2 tubes come in, they are from the same person.  
They also check the gender of the donor. 
 
 Dr. Bidichandani stressed that community involvement, education, outreach, and similar 
work should be included in the protocol design.  Dr. Kaye replied that those issues would be 
addressed in the logistics development of the project.  Only persons who are engaged in the 
National ALS Registry will be included in this biorepository. 
 
 Dr. Horn asked who the users of the proposed collection will be.  It is important to 
understand who the users would be, what they want, and what they need.  Dr. Kaye said 
that a process will be created for researchers to access the specimens. 
 
 Dr. Gubitz asked about control pools.  This aspect of the bioregistry may be dependent on 
the specimens that are collected.  Dr. Kaye said that controls would not be collected as part 
of this project. 
 
 Dr. Brujin wondered whether the pilot project should attempt to collect as much as possible 
rather than determine the specimens based on feasibility.  Dr. Kaye agreed that one 
approach could be to capture as much as possible in the pilot, and then whittle down the list 
for the full implementation. 
 
 Dr. Kasarskis referred to the table of relative advantages of different specimens.  He 
encouraged adding skin and muscle biopsies to the table.  He also pointed out that the ease 
of sampling should be taken into consideration.  Some advanced ALS patients may be 
better suited to a skin biopsy than a venous sample.  Additionally, associated side effects of 
sampling should be considered.  There is a defined complication rates for spinal taps, for 
instance, including headaches that can persist. 
 
 Dr. Corriveau suggested that the pilot collect as much as possible while utilizing best 
practice.  Data is available on best practices for biomarker discoveries and on the impact of 
following them or not following them. 
  





 Dr. Boylan agreed.  Regarding “future-proofing” the repository, he pointed out that medically 
viable samples are not necessarily research-viable samples.  There can be sensitivity to 
temperature exposure and time between actual collection and processing.  These factors 
can compromise the utility of the specimens.  DNA and RNA are less of a concern in this 
case than other protein biomarkers. 
 
 Dr. Bowser concurred that DNA and RNA can be collected in specific vials and shipped at 
room temperature, but depending on the downstream research questions, especially 
protein-related investigations, collection may be more sensitive.  Timing, processing, and 
storage are critical for that work.  To facilitate protein-based or biochemically-based 
markers, those important points should be taken into consideration.  Collecting as many 
samples and as many kinds of samples in the pilot is important, because the pilot is a 
feasibility study.  If 100 samples will be collected, should they collect 10 each of 10 types of 
samples, or more in order to properly assess feasibility? 
 
 Dr. Weisskopf added that processing time varies when collecting biochemical markers from 
large cohorts.  One approach is to collect volunteer samples.  When requests are made for 
samples from the biorepository, a series of pilots of the assay can be performed to 
determine whether the assay works, does not vary, and is not sensitive to factors such as 
processing time. 
 
 Dr. Bradley said that control groups are needed for any research. 
 
 Dr. Traino commented that if it not feasible to acquire control samples, it might be possible 
to collaborate with a group that collects healthy tissue for research purposes, such as the 
NIH Common Fund’s Genotype Tissue Expression Project (GTEx). 
 
 Mr. Tison asked about historical examples of correlation to environmental exposures to 
biosamples with neurodegenerative diseases to indicate that certain sample types are more 
useful than others. 
 
 Dr. Weisskopf said that from an environmental perspective, certain tissue types are more 
useful than others in yielding information about past history.  For example, bone tissue and 
teeth samples offer the possibility to consider past exposures as opposed to “what’s on 
board now,” which can be assessed by urine and blood. 
 
 Dr. Bouzyk agreed and suggested considering hair and nail clippings in the biorepositories.  
Regarding controls, they might consider collecting families or trios in order to add extra 
value to the studies. 
 
 Dr. Weisskopf observed that people in the National ALS Registry are likely to have 
caregivers or partners who might be interested in participating as a control.  While hair and 
fingernails are useful for determining past exposure, they still have a window of about 1 
year. 
 
 Dr. Horton said that the National ALS Registry does not collect control information.  That 
work is typically conducted by researchers for individual studies.  He understood that 
bioregistries are different, however.  CDC’s National Health and Nutrition Examination 
Survey (NHANES) collects certain biospecimens and he wondered whether it would be 
feasible to use that resource as a control. 





 Dr. Gwinn said that NHANES samples have not been fully exploited for use as controls in 
studies such as this one, but they could explore NHANES as a potential control group. 
 
 Dr. Horton explained that NHANES is an on-going, national survey that CDC administers 
yearly.  The survey includes a wide variety of questions and the collection of biological 
specimens. 
 
 Dr. Bradley commented that spouses may not be ideal controls because they have shared 
the same environment as the ALS patient for a certain number of years, which could pose a 
problem for environmental research. 
 
 Dr. Kamel said that not very many samples are useful for environmental measurements, as 
most samples only provide a picture of recent exposure.  Often, ALS researchers are 
interested in exposures throughout the lifetime.  In addition to clinical data, environmental 
exposure data should be collected and linked to the samples.  A modular questionnaire was 
developed at Stanford University that addresses occupational history and other sources of 
environmental exposures.  The modules are designed not to be burdensome and to be used 
in contexts such as this one.  This information will be critical in the future. 
 
 Dr. Horton said that the 7 modules currently used in the National ALS Registry were 
developed by Stanford.  Future modules will address lifetime residential history, 
occupational history, and other factors such as hobbies that may involve exposures.  Those 
modules could be used as surrogates, since urine and blood only indicate recent exposures. 
 
 Dr. Vaught commented on GTEx, which is a collaboration of NHGRI, the Genome Research 
Institute, the National Institute of Mental Health (NIMH), and NCI.  This project collects 35 to 
40 separate tissues, including skin and muscle, from rapid autopsy patients or organ 
procurement donations.  Brain tissue is also gathered when appropriate.  Metastatic cancer 
is an exclusionary criterion.  Tissues are viable for basic RNA integrity and RNA sequencing 
even if they are collected some time after death.  They are also starting surgical collections.  
The surgical patients are often having amputations, and skin and muscle are major 
components of those collections.  Data from this study will be available on dbGAP soon, and 
the tissues will eventually be available for sharing.   
 
 Dr. Berry felt that before deciding which specimens should be collected, they should think 
about the analyses that may be conducted on them.  The analyses will affect not only the 
specimens that will be collected, but also the way in which they are collected.  Gross 
technical factors could determine what is feasible and what is not feasible.  For example, if 
samples are collected when the donor has fasted for 12 hours, then good metabolomic 
studies can be conducted.  If the donor has not been fasting, then those studies cannot be 
performed.  Other considerations include the speed of the centrifuge; for instance, collection 
could be conducted in the home, but the person who does the collection may need a 
portable centrifuge.  He suggested breaking the research questions into kinds of analyses, 
such as metabolomics, proteomics, genomics, genetics, epigenetics, gene expression, 
micro RNA, and others. 
 
 Dr. Bidichandani said that in epigenetics, the chromatin immunoprecipitation (ChIP) process 
is preferred, and storage processes should be mindful of this. 
 




 Dr. Brujin thought that if the list were to be extended, it should include human tissue, both 
fresh and from a short autopsy time frame, for immunoprecipitation.  Dr. Bowser added 
“fixed and frozen.” 
 
 Dr. Horton understood that blood and urine samples provide a current picture of the patient.  
He asked what tissue can show in terms of exposure. 
 
 Dr. Kamel said that the information gleaned from tissue depends upon the exposure.  For 
example, lifetime lead exposure can be learned from bones and teeth.  The timeframe is 
different depending on the particular bone.  These samples can be collected non-invasively.  
Another example is organic chlorine pesticides or related compounds, which can be 
determined from fat tissue.  Taking a fat biopsy can be invasive, and blood samples are not 
strong.  There are few examples of environmental toxicants that are persistent enough in the 
body to be measured for long-term exposure. 
 
 Dr. Weisskopf said that a large sample of blood serum and plasma is needed for 
organochlorines.  Cadmium in urine is another example of a reasonable measurement from 
a sample.  He said that controls are critical for looking at ALS incidence from an 
epidemiological perspective.  Another consideration could be to think of the tissue as 
potentially predictive of survival of ALS.  Then, variation among the cases could be 
examined.  With that approach, blood, urine, hair, and nails could be relevant for 
environmental contaminants.  The collection methods for those samples are very precise 
and specific. 
 
 Dr. Bradley commented that organic chlorine pesticides have been demonstrated to be 
higher in Parkinson’s Disease patients than in controls.  He noted that brain banking is a 
difficult field, and suggested a different model for the development of funding for brain tissue 
banking for the National ALS Repository.  Fifty years ago, the autopsy rate was about 40%, 
and now it is less than 10%.  This change is due to a number of reasons, including public 
resistance, religious resistance, and physician resistance because imaging can yield 
information, so physicians may not feel that autopsies are necessary.  However, since the 
advent of imaging, published papers have indicated that 25% of autopsies reveal 
information which, if it had been known in life, would have played a role in the disease or 
condition management.  He suggested that an investigator who is interested in collecting 
tissue can be extremely effective.  He shared his experience in studying metal levels, which 
included collecting autopsies.  He and his colleagues developed a system in which patients 
were admitted to the hospital for their terminal care.  The time from death to autopsy was 
approximately 75 minutes, and rapid autopsies are important for RNA preservation.  Many 
ALS patients desire to donate their bodies after death, and the majority of them do not have 
that service provided to them because of challenges in linkage.  Therefore, a network of 
centers is needed to serve as collecting centers.  He suggested creating this network of 
funded neurologists who will serve as the basis for collecting patients centrally for brain 
banking. 
 
 Dr. Bowser agreed, noting that post-mortem brain and spinal cord collection depends on a 
dedicated service of experienced and willing providers.  A neuropathologist is needed in 
addition to the neurologists who can recruit patients.  Rather than a centralized process 
where samples are sent in typical post-mortem times of 24 to 48 hours, he advocated for 
utilizing multiple sites across the country that can collect and process samples immediately.  
A central or virtual repository could be created, but a system would need to be created to 




determine which samples could be kept in-house and which would be sent to the centralized 
repository. 
 
 Dr. Kaye asked how a representative sample of brains could be collected in this schema 
and how to reach people who do not have access to neurologists.  Dr. Bradley and Dr. 
Bowser indicated that those persons would not be reached by the system. 
 
 Regarding biomarkers, Mr. Tison asked whether researchers may desire to use longitudinal 
samples to correlate with ALSFRS progression rate from the 6-month repeated survey 
module. 
 
 Dr. Bradley and Dr. Bowser indicated that a number of researchers were interested in the 
correlation not only from a longitudinal perspective, but also post-mortem. 
 
 Dr. Kasarskis suggested organizing their approach by specimen and by the types of 
research questions that can be answered by a given specimen.  Then the plan can flow 
according to the viability of the specimen, whether it is adaptable to future technologies or 
future genetic identifications, and other considerations.  Post-mortem tissue is important for 
confirmation.  Questions of what is inexhaustible, the ease of sample collection, side effects, 
morbidity, cost, post-mortem interval, et cetera, can be answered for each type of specimen. 
 
 Dr. Gwinn said that the draft protocol begins that analysis, based on the available literature.  
They know what can be measured by certain biofluids, and they know types of markers that 
can be correlated with different kinds of exposures, but specialized and tissue-specific 
elements have not yet been incorporated into the protocol.  It also does not take into 
account specific factors such as the potential need for an onsite centrifuge, or special tubes 
for RNA collection or collection of samples for metal analysis. 
 
 Dr. Kasarskis commended Dr. Gwinn for the draft protocol and suggested that the expert 
panel could begin to fill in the gaps. 
 
 Dr. Brujin clarified that they could standardize a set of questions for each sample type. 
 
 Dr. Brooks asked whether the registry is for use by the agency for environmental disease 
correlation, or whether the samples will be available for the scientific community to request 
for hypothesis-driven research. 
 
 Dr. Horton answered that ATSDR looks to the expert panel for advice regarding how the 
bioregistry can be useful to the field.  Samples that are collected will be available to the 
general scientific community for research.  The bioregistry could operate through a “check 
box” in the National ALS Registry so that upon joining the registry, participants can indicate 
their willingness to donate samples and the kind of samples they are willing to donate. 
 
 Dr. Horn asked whether the purpose of the collection is to link samples to the National ALS 
Registry to make them available to researchers, or whether the purpose is to create a 
bioregistry that does not exist and that represents the best resource for researchers.  If 
samples already exist, why should this bioregistry be created? 
  





 Dr. Brujin said that the National ALS Registry brings people with ALS and information to a 
central place.  Other collections are important, but the registry represents an opportunity to 
involve ALS patients in studies.  Further, a partnership for accomplishing the bioregistry will 
be valuable.  It is important to connect to other efforts. 
 
 Dr. Bradley added that the registry has the advantage of being a national database with 
non-selected patients.  The endeavor will have funding, and epidemiological data will be 
available for patients in the bioregistry. 
 
 Dr. Kamel wondered whether it would be valuable to use some of that funding to collect 
samples from control patients, even if it meant that fewer samples and fewer types of 
samples could be collected for ALS patients, to achieve comparability.  Studies can be 
conducted with only ALS samples, but more studies are possible with controls.  Part of the 
problem with controls is that people who do not have a disease tend not to be interested in 
donating samples, particularly if they are invasive.  One strategy for this challenge is to 
enroll a spouse or friend of the case.  There are limitations to this approach, even when the 
control cases are eager to participate.  An extension of this strategy is to ask the person 
close to the ALS patient to recruit someone to participate as a control rather than to use a 
co-worker, spouse, or family member who may have had the same environmental 
exposures as the ALS patients. 
 
 Dr. Bowser said that the RFA stipulates that people in the bioregistry must be in the National 
ALS Registry.  Therefore, the feasibility study will not likely include a control population.  The 
pilot study should consider additional important characteristics of samples that might be 
acquired that are less represented in other biorepositories.  The epidemiological information 
that is collected with the samples is critical, so the specimens that are collected could be 
determined based on their relevance to epidemiologically-focused studies.  Whole blood 
would be useful, for instance, and post-mortem teeth collection could assess lifetime 
exposure to metals.  That work would make a major impact on the field. 
 
 Ms. Ritsick noted that the deliberations of the panel can affect the scope of the contract and 
the number of samples to be collected. 
 
 Dr. Kasarskis recalled that the Coriell repository required a convenience, non-ALS sample 
blood tube.  Dr. Corriveau said that the NINDS Repository welcomes convenience controls, 
but does not require them.  Dr. Gubitz added that the repository includes neurological 
control samples. 
 
 Dr. Kasarskis recalled a comparable page of clinical data elements.  He envisioned that an 
ALS patient in the National ALS Registry could recruit a non-ALS control, which would 
require broadening the scope of the registry to include a parallel arm. 
 
 Dr. Kamel noted that there are often problems associated with collecting samples from 
people who already have a disease because it is not known how their condition has 
impacted the sample.  Data such as history of exposure can be correlated with the sample 
and compared to NHANES data to determine whether samples that have been collected 
after diagnosis have been altered in ways that make them less useful because they are not 
prospective. 
 




 Dr. Horton said that they would evaluate what NHANES is collecting and whether those 
biological specimens might be useful as a control.  Mr. Kingon added the possibility of 
adding specimens to NHANES in the future. 
 
 Dr. Weisskopf pointed out that there will be always be concerns about how the NHANES 
samples were collected and processed. 
 
 Dr. Traino commented that normal tissue can potentially be collected from organ and tissue 
donors.  While they are focused on the tissue, they should not forget the people who are 
providing the tissue and what they can provide.  Her group is conducting surveys with family 
members of deceased ALS patients who donated tissue. 
 
 Dr. Horton asked about gaps in the field, such as specimens that are not being collected 
and should be collected and researched. 
 
 Dr. Brooks responded that the gut microbiome in ALS compared to other diseases is not 
being collected. 
 
 Dr. Weisskopf noted that if biological samples will be collected from controls, and the 
controls are not necessarily random, then it will be important also to utilize the modules that 
are used with the ALS patients. 
 
 Dr. Bouzyk added the gap of CLIA, and the pros and cons of running a national 
biorepository to CLIA standards.  There are pros and cons to the approach, as CLIA does 
bring confidence to biomarkers.  Additionally, it would be interesting and helpful to learn 
about global best practices as a reference point. 
 
 Dr. Kaye asked whether it is important to immortalize the cell line. 
 
 Dr. Corriveau responded that it is important not to immortalize a lymphoblastoid cell line.  In 
modern genetics, there are frequent needs to use DNA directly from tissue or whole blood 
that has not been changed.  If there is a need for cells, it may be worth considering other 
options, such as skin biopsies for fibroblasts. 
 
 Dr. Bouzyk concurred with the importance of being able to go to the source.  He agreed with 
extending the table of specimens to be collected and with thinking holistically about what is 
being collected.  For instance, if blood and blood products are being collected, the rationale 
for collecting saliva as well is not strong. 
 
 Dr. Kaye asked whether it is worth collecting saliva if blood cannot be collected. 
 
 Dr. Bouzyk said that it is worth it, and a prioritized approach could be part of the protocol. 
 
 Dr. Berry reminded the group that at times, it is easier to get a skin biopsy than a blood 
sample. 
 
 Dr. Weisskopf suggested that the pilot could try to collect all of the samples to determine 
which ones tend to work. 
 




 Dr. Corriveau said that the DNA yield from blood is higher than from saliva.  Dr. Vaught 
added that bacterial DNA can be captured by the mouthwash protocol.  Dr. Horn noted that 
processing saliva samples for DNA is usually more expensive. 
 
 Dr. Vaught commented that their pilot studies led them to use PAXgene® Tissue to preserve 
and ship tissue to the analysis laboratory.  The samples last for several days and up to a 
week at ambient temperature.  The RNA quality and integrity is very good. 
 
 Dr. Gallagher said that if saliva collection will be offered to people who are uncomfortable 
with donating blood, the choice may have to be presented to participants upfront.  This 
choice could potentially bias the collection toward saliva, which is clearly a suboptimal 
specimen.  If blood is collected for serum, then the clot can be recovered as an additional 
source of DNA. 
 
 Dr. Kasarskis commented that skin sample collection is a physician procedure. 
 
 Dr. Horn noted that there are models for collecting tissue outside the point of care.  For 
instance, the Susan G. Komen Foundation maintains a normal tissue breast bank.  They 
conduct core biopsies of breasts of normal women at community outreach events. 
 
 Dr. Corriveau pointed out that if there are problems with collecting blood, the problems could 
mushroom into more serious concerns for the project as a whole.  Serum and plasma are 
the most important samples to collect for biomarkers, epigenetics, genetics, and other 
critical areas. 
 
 Dr. Bouzyk believed that blood is the gold standard for collection.  Some studies utilize an 
electronic consent form that first asks potential participants whether they are prepared to 
give blood.  If they reply “no,” then the next question asks whether they are willing to donate 
saliva. 
 
 Dr. Corriveau said that in biomarker work, it is important to find people as early as possible 
after diagnosis and collecting samples of blood for serum and plasma every 4 months. 
 
 Dr. Weisskopf agreed that if the consent form presents the possibility of giving either blood 
or saliva, then there will be bias against donating blood.  It could be argued that blood and 
saliva are both needed, for different reasons. 
 
 Dr. Kaye envisioned presenting a list of tissues to be collected so that participants can 
contribute the biospecimens that they are interested in providing. 
 
 Dr. Gwinn asked whether there is a reason to collect saliva if a blood sample is available. 
 
 Dr. Corriveau said that if a particular visit does not include blood collection, and a back-up is 
needed to ensure that samples are being collected from the same person, then saliva could 
serve as that confirmation. 
 
 Dr. Berry said that there are medium-sized banks of fibroblasts, skin biopsies, and 
immortalized cell lines.  It may be beneficial to reach out to some of these banks and learn 
about their work, as the work is very expensive, and they should consider resource 
utilization. 
 




 Dr. Brujin explained that skin fibroblasts are used to generate the embryonic stem cells, 
which can then be differentiated to make motor neurons and a variety of cell types.  They 
should determine how many of these lines they want.  NINDS and other groups are 
investing in supporting and generating the Coriell induced pluripotent stem (iPS) cell line 
and differentiating the cells.  There is a question of what will be gathered in addition and 
whether environmental data is needed.  The iPS lines are not necessarily valuable for 
determining exposures, but for developing phenotypes.  The environmental and clinical data 
may not be helpful in this instance. 
 
 Dr. Kasarskis said that fibroblasts can be collected and banked without the intention to 
create iPS cell lines.  That project may never be within the scope of the bioregistry.  
Collecting fibroblasts could set the stage for future research. 
 
 Dr. Gwinn said that one of the potential uses of the biorepository is to validate 
measurements that have been made or to look at a larger distribution of values in an 
unselected population.  She asked about particular measures that this might be suitable for.  
For example, some genotypes have been associated with both familial and sporadic ALS 
cases.  It might be beneficial to have a national estimate of the frequency distribution of 
those mutations. 
 
 Dr. Brooks returned to the issue of the purpose of the biorepository.  The field needs  
peripheral blood, mononuclear cell protein, and RNA pellet from as many National ALS 
Registry participants as possible.  With that sample and the addition of a skin biopsy before 
and after gastroscopy may provide a core of samples that would be desired by the field. 
 
 Dr. Bowser said that for validation purposes, CSF or blood would be needed. 
 
 Dr. Boylan said that the biomarker literature includes cross-sectional studies of moderate 
size.  Collecting samples from more than 1 time point in the same patient can be challenging 
because they are expensive and time-consuming.  If this bioregistry built in multiple time 
points for longitudinal foundations, it would represent a great contribution to the field. 
 
 Dr. Kaye asked about ideal time periods for specimens to be collected. 
 
 Dr. Boylan said that ultimately, the intervals should be clinically relevant, perhaps 3 – 4 
months apart.  The collection points should follow the patient through the course of the 
disease, and that interval varies from patient to patient.  The ideal biomarker study would 
enroll patients early in their disease and follow them on a 3- to 6-month basis until death. 
 
 Dr. Horton said that currently registry participants take the ALSFRS module every 6 months. 
 
 Dr. Bowser said if only 2 samples could be collected, then a change in the FRS could trigger 
collection of the second set of samples.  That approach would ensure that samples would 
be collected at different disease stages.  If only a small number of samples will be collected, 
he hoped to follow the disease as far along as possible.  A clinical FRS assessment could 
identify a unit of change to indicate significant progress of the disease.  If only 2 samples are 
taken, and they are taken at intervals in which the disease has not progressed significantly, 
then they samples will be less useful than if they were collected at different disease stages. 
  





 Dr. Corriveau reminded them of the importance of best practices.  For instance, no more 
than 2 hours should elapse between the vein puncture to centrifuge and allocation to 
appropriate tubes, preferably in liquid nitrogen.  The results of the work will reflect the quality 
of the samples that are collected. 
 
 Dr. Bradley said that the feasibility of repeated collections of CSF is a major issue.  
Increasing numbers of pharmaceutical industry studies in ALS require CSF collection.  It 
might be possible to get permission to obtain residual specimens from that work. 
 
 Dr. Sejvar reinforced the importance of specimen handling and stringent SOPs, as well as a 
means for documenting the conditions under which the specimens were collected, which 
can reflect on the results that are obtained. 
 
 Dr. Horton said that the sample size for the feasibility study was suggested to be 150.  He 
wondered about the most appropriate use of the sample. 
 
 Ms. Ritsick clarified that the numbers could change, and multiple samples could be taken. 
 
 Dr. Brooks said that some of his gene expression studies need a sample size of 8 to 15 for a 
gene that is approximately 30% overexpressed.  For a protein, the sample size is 25 to 30. 
 
 Dr. Bowser asked that if 4 samples are collected from 1 person over time, whether that work 
is 4 samples, or 1 sample.  Dr. Kaye replied that the budget allows for 150 people providing 
multiple specimens.  The panel’s recommendations can change the deliverable. 
 
 Dr. Brooks said that some data are available from NEALS and from Dr. Vaught.  He further 
noted that some samples will not be able to be used. 
 
 Dr. Corriveau said that it is possible to decide whether to collect fibroblasts from a particular 
individual based on what is learned in the first few months of the project. 
 
 Dr. Berry suggested that they define how much tissue would be collected, versus how much 
biofluid. 
 
 Dr. Bowser added that if brain tissue is to be collected, then only the patients who die within 
the contract frame will be able to have their tissue collected.  Ms. Ritsick responded that 
arrangements have been made for ATSDR to continue collection beyond the contract 
period. 
 
 Dr. Bouzyk reminded them of the importance of “future-proofing” the biorepository for 
downstream technologies.  If they will collect fresh frozen tissue, will they collect Formalin 
Fixed Paraffin Embedded (FFPE) tissue as well?  Many molecular-based studies are being 
conducted on FFPE tissue, and some of the latest technologies are on the cusp of using 
FFPE tissue. 
 
 Dr. Corriveau asked to whom the kits would be shipped.  Dr. Kaye replied that they would be 
shipped to the person collecting the specimen, not to the donor. 
 
With no further business posed, Mr. Kingon adjourned the meeting for the day. 
 











Wendy Kaye, PhD 
Senior Epidemiologist 
McKing Consulting Corporation 
National ALS Registry Program 
Agency for Toxic Substances & Disease Registry 
 
Dr. Kaye reviewed the previous day’s discussion.  She reminded the panel that participants in 
the proposed biorepository must be participants in the ATDSR National ALS Registry.  The 
biorepository must be a representative sample of the registry, so participation cannot be limited 
to geography, level of care, or other issues.  They are creating a pilot project to test the 
feasibility of a biorepository, not to conduct analyses or studies. 
 
If the biorepository goes forward, then it might be built into the National ALS Registry so that 
participants can indicate willingness to donate specimens when they join the registry.  Another 
consideration regards how to harmonize the proposed bioregistry with other, existing 
bioregistries.  The goal of the proposed biorepository is to link specimens to the National ALS 
Registry.  Partnerships are valuable, and it is important to connect with others.  One of the 
advantages of this biorepository is that it will include national, non-selected patients.  It is 
funded, and it is supported by a wealth of epidemiological data on the participants. 
 
Discussion was rich regarding research questions that might need to be answered and that 






 Gene expression 
 Environmental issues 
 Micro RNA 
 Issues of survival 
 Human tissue, fresh and frozen 
 
Discussion also focused on the sample size and the need for a control.  The size of 300 was 
suggested.  There was discussion regarding whether other data should be collected, and it was 
suggested that the ALSFRS should be collected every 6 months.  Environmental data should be 
collected via questionnaires, as specimens mainly assess only recent exposures. 
 
Regarding specimens, some panel members felt that it is important to collect as many samples 
as possible.  Best practices were discussed, and it was noted that medically viable samples 
may not be suitable for research purposes.  The need for a control group was emphasized, and 
the possibility of using NHANES as a control group was posited.  Longitudinal specimens and 
recruiting possible controls were discussed.  The panel also noted that immortalizing cell lines 
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would not be the best use of resources, and it would be preferable to have fibroblastic cells.  
DNA should come from the source rather than from immortalized cell lines.  Blood is the 
preferred sample.  There was discussion about PAXgene® tissue collection and about whether 
an IRB would require saliva as an option for people who do not want to give blood. 
 







 Muscle  
 Residual specimens from drug company research 
 
Regarding brain banking, the discussion raised the issue of collecting other specimens post-
mortem as well, such as teeth and bones.  If control specimens are collected, organ donor 
patients could be a possibility.  The panel also discussed gaps, including the gut microbiome 
and whether tests should be conducted using CLIA standards. 
 
The specimens desired by the panel included: 
 
 RNA 
 Skin biopsies 
 CSF 
 Blood 
 Longitudinal collection of some specimens every 3 to 6 months, perhaps linked to 
performance on the ALSFRS 
 
Other comments included information that would need to be collected so that researchers could 
develop their own controls and would know how specimens were collected and processed.  
Additionally, there were comments regarding how specimens will be shared.  The topic of 
specimen-sharing will be discussed at a later time. 
 
Dr. Kaye reviewed the revised draft table of specimen types and their relative merits and 






 Dr. Kaye stated that the information provided by the panel will be used to develop the final 
protocol for the feasibility study. 
 
 Dr. Gubitz commented that the goal of the specimen should be defined.  For instance, teeth, 
hair, and nails are collected for exposure data.  Since the National ALS Registry includes a 
great deal of epidemiological data, it would be helpful to collect biosamples to reflect that 
data. 
 
 Dr. Kasarskis also hoped to identify the research function of each of the specimens.  He 
recalled discussion about specimen types that could have broad potential for future use.  





 Dr. Brujin added that the longevity of the specimen was also important, as some specimens 




 Dr. Kaye directed the group’s attention to the column about blood. 
 
 Dr. Kasarskis agreed that the time frame for collecting a blood sample can vary according to 
the patient.  In the best case, it should take 10 minutes to capture blood; however, acquiring 
blood from an advanced ALS patient can be more challenging and take upwards of 15 to 20 
minutes, and the process may not be successful.  He suggested a time range of 10 to 25 
minutes.  Blood can also be collected longitudinally. 
 
 Dr. Horn suggested dividing the category of blood into subtypes.  There had been discussion 
of PBMCs as well as collecting serum for biomarkers.  The different derivates will affect the 
collection methods. 
 
 Dr. Gubitz suggested DNA and biomarkers as two goals for blood specimens.  Dr. Bowser 
added that blood can sometimes be used for environmental exposures. 
 
 Dr. Weisskopf noted that some analyses require a larger volume of a sample than others.  
Environmental analyses of blood, for instance, may require more samples.  Metals require 1 
or 2 milliliters of blood.  Organochlorines or other organics may require even more. 
 
 Dr. Kasarskis noted that some recent clinical drug trials drew 8 tubes of blood from a patient, 
so precedent has been set for drawing relatively large samples. 
 
 Dr. Weisskopf agreed and noted that for the purposes of “future proofing,” as techniques 
improve, less sample is required.  Dr. Vaught noted that aliquots should be saved for future 
uses. 
 
 Dr. Bouzyk asked for clarification regarding “candidate biomarkers.”  He said that a wealth of 
biomarkers is available from blood and blood products, and more will likely be used in the 
future. 
 
 Mr. Hixon commented that handling of the blood specimen depends on the type of blood that 
is being collected.  Dr. Bowser agreed that handling and processing can vary widely 




 Dr. Kaye turned the group’s attention to CSF and asked about the timeframe for its 
collection. 
 
 Dr. Kasarskis suggested a collection timeframe for CSF of a minimum of 30 minutes, noting 
that 2 people are required for the collection.  If a patient is in respiratory distress or 
discomfort, then the process can take longer.  Dr. Thurman noted that it is not practical to 
collect CSF in the patient’s home. 





 Dr. Kaye added that CSF could be collected longitudinally and clarified that the goal of 
collecting CSF is biomarkers with the panel.  She asked about future use of CSF. 
 





 Dr. Kaye turned to urine collection, which takes about 5 minutes.  It is easy to collect, and 
multiple samples are possible.  The specimens can be used for environmental studies. 
 
 Dr. Brooks said that urine has a long history in ALS studies.  Dr. Bowser added that urine 
can be used for metabolic studies. 
 
 Dr. Sowell suggested that urine is not very useful for environmental studies for ALS, 
because it can only yield information about recent exposures, which are not likely to have 




 The panel agreed that the collection time for saliva is 5 minutes, and it can be collected 
longitudinally and easily.  Saliva can be assessed for DNA and some biomarker work. 
 
Skin and Muscle 
 
 Dr. Kasarskis said that the goal of collecting skin and muscle is to get fibroblasts and 
cultures, which will take several weeks of work by a laboratory.  Dr. Gubitz agreed, adding 
that processing requires dedicated effort. 
 
 The panel agreed that potential for DNA and RNA is high, and collection can take 10 to 15 
minutes.  The time for collection for a needle biopsy was 15 minutes.  There is no need to 
collect these samples longitudinally.  The goal of muscle specimen collection is biomarkers. 
 
 Dr. Kasarskis said that it would be possible to get repeated skin biopsies if needed, but if the 
RNA and DNA cells are being stored, there should not be a need for longitudinal collection. 
 
 Dr. Bowser asked whether they were considering biopsy or postmortem samples.  Dr. 
Kasarskis recalled that the original comment was as biopsy, but he was not sure if a needle 
punch or open biopsy was planned. 
 
 
 Dr. Bouzyk felt that muscle was as easy as skin to collect. 
 
 Dr. Bowser said that muscle stores well.  Dr. Kaye asked whether muscle is likely to be 
useful in the future. 
 




 Dr. Brujin felt that muscle would be useful in the future, as muscle is highly relevant to ALS.  
As more is learned about the disease, it is likely that muscle will become even more 
relevant. 
 
 Dr. Bowser commented on his experience returning to muscle biopsies, which had been 
valuable. 
 
 Dr. Kasarskis asked whether the end product of a punch muscle biopsy was growing 
myocytes or myoblasts in cultures.  Someone could differentiate iPS cells into motor 
neurons and examine them with the target muscle in culture as a potential synapse 
formation. 
 
 Dr. Bowser and Dr. Brujin commented that muscle would not be used for that function, and 
that iPS cells were used for differentiation.  Dr. Brooks said that in muscle disease, it is used 
for biochemistry and for making sections. 
 
Teeth and Bone 
 
 The panel agreed that DNA and RNA could be collected from teeth, but it is not likely to be 
worth it.  The time of collection is not relevant, as teeth are collected post-mortem. 
 
 Dr. Weisskopf noted that if bones are collected post-mortem, then it is possible to conduct 
more extensive analysis on them and to learn about exposures other than lead.  In theory, 
any bone can be useful; however, harder, cortical bone is ideal. 
 
 Dr. Kasarskis noted that pathologists may take a sample from the vertebral body.  That 
sample is easy to collect, as the vertebral body has to be removed to reach the spinal cord. 
 
 Dr. Thurman wondered whether teeth and bone should be separated.  While teeth are 
helpful in examining heavy metal exposure in children, for instance, teeth may not be as 
useful for analyzing adult exposures. 
 
 Dr. Weisskopf said that teeth are still good samples for adult populations, as exposure can 
be measured below the enamel. 
 
 Dr. Thurman suggested that they qualify the environmental exposures.  Teeth and bone are 
good for assessing exposure to heavy metals.  Dr. Weisskopf added that organics are a 
potential future exposure that can be assessed by teeth and bone. 
 








Hair and Nails 
 
 Dr. Kaye asked about the future use of hair and nails, which are easy to collect and store. 
 
 Dr. Thurman said that hair and nails are good for determining intermediate exposures going 
back a few months, perhaps a year.  He was not certain whether there was value to be 
gained regarding remote exposures. 
 
 Dr. Weisskopf said that if the issue is incidence of ALS, then hair and nails are not likely to 
be useful.  If the issue is survival, then they could be useful. 
 
 Dr. Weisskopf said that the time of collection for hair could vary if patients do not have 
enough hair. 
 
 The panel agreed that hair could be collected longitudinally.  No biomarkers to date are 




 The panel agreed that the potential for DNA and RNA is high with brain tissue, and the 
potential for future use is high.  The goal of the collection the specimen is to gain insight into 
the pathophysiology of the disease. 
 
 Dr. Brady said that the actual procedure for collection is approximately 1 to 1.5 hours, but 
the time of collection may not be relevant, as the samples are collected postmortem. 
 
 Dr. Bowser said that the candidate biomarkers should be a “3” because the analysis 
includes not only candidates, but also which cells are making them and at what times, if they 
are found in other biofluids.  Dr. Weisskopf added that brain tissue can be useful for 
environmental exposure assessment. 
 
 Dr. Kasarskis confirmed that spinal cord will be collected as well as brain. 
 
 Dr. Bowser asked whether the VA collects muscle, and Dr. Brady indicated that they do not.  
Dr. Bowser said that his team will collect deltoid and quadriceps samples from the same 
side. 
 
 Dr. Brady said that the practicality of handling and processing brain tissue depends on how 
it is collected.  At some point, they should discuss types of storage, such as centralized 
versus decentralized.  He disagreed with some previous points that were made regarding 
quality of tissue and centralized processing.  The experience at the VA Brain Bank includes 
plenty of research-quality tissue with high RNA Integrity Number (RIN) values.  They have 
considered post-mortem intervals (PMIs), which are important, but are not the primary driver 
of tissue quality.  There are some extended PMIs in some of their collections; factors such 
as the tissue pH are more tightly related to RIN values.  Tissue pH has been more related to 
agonal state than to PMI.  The agonal state is an issue in ALS patients regardless of PMI.  If 
a decentralized collection process is desired, then that process may contribute to the “status 
quo of haves and have-nots in the field.”  Having a centralized brain collection allows all 
researchers to have access to tissue.  It is difficult for people in the field to get tissue, and it 




is important to think about the kind of biorepository they want to build and the ability to get 
tissue to researchers who need it.  A centralized bank to which researchers can apply will 




 Dr. Kaye reminded the panel that although the table refers to CSF collection from a 
bioregistry participant, CSF can also be collected post-mortem. 
 
 Dr. Kasarskis suggested adding olfactory nerve biopsy.  Dr. Berry said that adding that 
sample would depend on how broad the list should be.  A procedure room is needed for that 
collection.  Its potential is good, however. 
 
 Dr. Horn recalled that the bioregistry will be national.  Some of the elements they had 
described were specialized, and she wondered how to prioritize the top specimens with that 
in mind. 
 
 Dr. Gwinn replied that given the project parameters, they should balance what is feasible 
and what is desirable. 
 
 Dr. Kaye reviewed information from the table, noting that that collection could take place 
either in the field or in a doctor’s office, and the collection would have to occur in any part of 
the US.  To be representative, collection from living patients cannot be limited to the ALS 
Centers.  Collection could take place in a family doctor’s office and not necessarily in a 
specialist’s office.  Regarding postmortem samples, a network of dieners will conduct that 
collection. 
 
 Dr. Weisskopf suggested that the table combine teeth, bone, and brain into a category of 
“autopsy.” 
 
Panel members voted on their top 4 specimens to collect for the proposed biorepository.  Dr. 
Kaye reviewed the results of the voting: 
 

















 Dr. Kaye addressed a question regarding how many longitudinal specimens could be 
collected per person.  Given the constraints of the approval process and the length of the 
contract, it could be possible to collect 2, perhaps 3, specimens from every participant at 6-
month intervals.  She asked the group to discuss amounts of samples that would be ideal to 
collect. 
 
 Mr. Tison commented that ALSFRS is already collected every 6 months.  It is misidentified 
as “quality of life.”  Dr. Kaye agreed, noting that blood specimens could be collected every 6 
months, timed with the administration of the ALSFRS. 
 
 Dr. Kaye asked whether collecting 40 milliliters of blood would be acceptable. 
 
 Dr. Horn asked whether anything about this population would limit the amount of blood that 
could be drawn.  The panel indicated that there was not. 
 
 Dr. Bowser suggested thinking in terms of vials collected rather than total volume.  The 
tubes used to collect for whole blood are different from the tubes used to collect for plasma. 
 
 Dr. Bouzyk agreed that 40-45 ml is the typical amount that is drawn in studies.  Dr. 
Gallagher said that the NHANES study for adults collects up to 100 ml.  Mr. Hixon said that 
clinical trials conducted through his group collects 120 ml. 
 
 Dr. Sowell said that if longitudinal samples will be collected, then a larger amount should be 
collected initially, with lesser amounts collected subsequently, as some elements change 
over time and some do not. 
 
 Dr. Kaye referred to Table 8 in the protocol, which lists 3 tubes at 23 ml total as a minimum. 
 
 Mr. Tison commented that blood draws are more difficult and less productive as ALS 
progresses.  Dr. Kaye agreed and noted that the study will include people in all stages of the 
disease. 
 
 Dr. Berry said that his group has permission to collect up to 120 ml.  When that volume is 
collected at baseline, smaller collections are taken later.  The amounts are based on need, 
and a practical concern is the difficulty of blood draws later in the disease.  He suggested 
setting an upper limit, but building flexibility into the plan to account for disease condition. 
 
 Dr. Gubitz expressed concern that patients might be deterred from participating in the study 
if they are expected to donate a great deal of blood. 
 
 Dr. Corriveau suggested that at the first visit, 1 tube of 5-6 ml should be drawn for DNA.  As 
the list includes biomarkers, they should discuss whether both serum and plasma are 
desired, or whether one of them is good enough.  This approach may be preferable to 
collecting as much blood as possible. 
  





 Dr. Kasarskis said that advanced ALS patients may have trouble with venous access.  
Sometimes the only accessible vein is on the back of the hand, and 2 people may be 
needed for the collection.  There is pain and discomfort associated with finding the vein, and 
the process of the draw itself can be slow. 
 
 Mr. Tison added that dehydration is common as the disease progresses. 
 
 Dr. Horn said that in determining the amount of specimen, they should also consider yield 
and how many experiments are downstream.  They should think about who will use the 
resource and how they will use it, even for the pilot study. 
 
 Dr. Gubitz pointed out that the next generation of sequencing methodologies does not use 
DNA from lymphoblastoid cell lines.  Dr. Bidichandani agreed that they are abnormal cells.  
Fibroblasts can be made from skin. 
 
 Dr. Bouzyk agreed that they should delve into some details in order to be selective about the 
types of tubes that are used.  If the first tube is used for DNA, the DNA could be extracted 
from it, or it could be spun for buffy coat (for future DNA isolation) and plasma -if the tube is 
a purple top EDTA tube. 
 
 Dr. Berry said that it is difficult to set a minimum amount for blood, because they may not get 
any, or very little.  The priorities are important, but from a practical perspective, blood is 
drawn in a certain order based on the tubes and the additives in the tubes.  It is difficult to 
know a priori how much blood will be collected.  For instance, Ethylenediaminetetraacetic 
acid (EDTA tube) needs to be drawn before a heparin tube.  If both are desired, but the 
heparin is more important, the EDTA still needs to be drawn first. 
 
 Dr. Kaye said that the pilot test will illuminate these issues.  They can evaluate whether all 
donors are able to fulfill all of the desired samples.  She said that the protocol includes tubes 
in order:  EDTA, clot activator, and acid citrate dextrose.  She asked whether this list was 
acceptable and whether tubes should be added or removed.  
 
 Dr. Berry suggested adding at least one PAXgene® tube for RNA.  Dr. Gallagher noted that 
the acid citrate dextrose tube could then be eliminated. 
 
 Mr. Hixon added that the PAXgene® tube is a 10 ml tube, but it includes 3 ml of 
preservative, so the total draw is 7 ml. 
 
 Dr. Berry commented that the NEALS Biobank receives many requests for plasma.  They 
collect plasma in EDTA, as sodium heparin tubes have been less versatile.  Dr. Bowser 
agreed that if multiple tubes will be collected, then ETDA is the preferable tube type. 
 
 Dr. Kaye confirmed that if a fourth tube is taken in the minimum protocol, it should be a 
second EDTA tube.  That addition brings them to 34 total ml. 
 
 Dr. Kamel suggested collecting at least one tube to measure metals.  Whole blood is 
needed, and it should probably be from the first tube to avoid contamination.  If some of the 
other tubes do not work out, then whole blood can be used for DNA.  One or two ml is a 




sufficient amount to collect for assessment of metal exposure.  If a study considers the 
effects of toxicants on survival, then the measurement could be useful. 
 
 Dr. Sowell felt that metals should not be collected in the first tube.  Dr. Weisskopf 
commented that different tubes could be used for certain organics that are longer-term 
markers than metals. 
 
 Dr. Sowell said that if multiple tubes will be collected, then a butterfly will probably be used.  
Blood left over in the butterfly can be collected, and bloodspot papers can be stored.  Finger 
stick collections could be used as well for small volumes. 
 
 Dr. Weisskopf said that 2-3 ml may just yield 1 run of trace metals. 
 
 Dr. Bouzyk said that if PAXgene® is used for RNA downstream, they might consider a cost 
analysis of Tempus™ tubes as an alternative. 
 
 Dr. Gallagher noted that the residual clot from tube 2 could be stored as a backup in case 




 Dr. Kaye turned to the postmortem specimens.  After blood, they received the most votes, 
indicating that the panel agreed that the biorepository should include postmortem 
specimens.  Brain and spinal cord samples were suggested in order to align with the VA 
Biorepository.  She asked about additional postmortem samples that may be needed in 
addition to brain and spinal cord, CSF, teeth, bones, skin, and muscle. 
 
 Dr. Kasarskis observed that the samples will not be collected in the same way.  The 
vertebral body bone is easy to collect.  Psoas muscle is available as part of access to 
reperitoneal space.  He was not sure whether pathologists would embrace the collection of 
teeth, and there could be pushback from a cosmetic standpoint. 
 
 Dr. Weisskopf said that molars can be collected to address cosmetic concerns.  Another 
issue is that teeth may need to be extracted by someone with expertise in extraction. 
 
 Dr. Bowser asked whether collecting either bone or teeth would preclude the necessity for 
the other.  Dr. Weisskopf said that one does not necessarily preclude the other.  Bone may 
not be necessary if teeth are available, but bone may be easier to collect.  One tooth is 
sufficient, and canines are preferable, but molars are acceptable. 
 
 Dr. Brady turned to the issue of practicality, as teeth are outside the normal autopsy.  
Collecting a spinal cord can be challenging, and adding teeth to the protocol may increase 
the fail rate. 
 
 Dr. Bradley agreed, noting that adding teeth to the protocol may discourage dieners in their 
network.  He asked what can be done with teeth that cannot be done with bone and whether 
teeth are essential. 
 




 Dr. Weisskopf said that teeth are preferable for assessing adult exposure, as bone “turns 
over” more. 
 
 Dr. Bowser did not think that skin would be needed postmortem if it has already been 
collected.  He asked Dr. Brady about the possibility of asking the dieners in the network 
about collecting teeth as part of the feasibility study.  Dr. Brady said they could ask the 
dieners about their willingness to conduct teeth collection. 
 
 Dr. Kamel understood that collecting teeth could be too much to ask of the dieners, but 
metals, especially lead, turn over in bone and do not in teeth.  Any lead in a tooth started 
being there in childhood. 
 
 Dr. Kasarskis noted that postmortem fat can be acquired.  Dr. Thurman said that fat could 
be useful for longer-term organic exposures. 
 
 Dr. Brady said that the standard VA pathology departments would probably be comfortable 
with these collections.  Regarding the diener networks, there were challenges with 
convincing them to collect the spinal cord.  Some will be willing to collect teeth as well, and 
some will not. 
 
 Dr. Bowser felt that the area was valuable to explore, as a great benefit of this biorepository 
is its connection to the National ALS Registry and its epidemiological modules.  They should 
enhance the ability to use the modules by collecting samples that address those questions.  
Even though the work is challenging and different from what people are accustomed to, it 
has the potential to make a significant impact on the field. 
 
 Dr. Kasarskis asked fibroblasts can still be grown from skin is the PMI is 6 hours.  Dr. 
Bradley said that nails continue to grow for 2-3 days, so there is viability. 
 
 Dr. Kasarskis asked about the purpose of collecting muscle.  Dr. Bowers answered that 
muscle addresses the pathobiology of the disease. 
 
 Dr. Kasarskis added that skin can be collected from the omentum around the intestines. 
 
Saliva, Urine, and Hair, and Nails 
 
 Dr. Kaye reviewed the three specimens with the fewest votes:  saliva, urine, and hair and 
nails.  The only reason to collect saliva is if blood cannot be collected.  Since this project is a 
pilot, saliva may not be necessary as part of the feasibility study. 
 
 Mr. Hixon noted that these specimens can be self-collected. 
 
 Dr. Thurman asked whether a buccal scraping would be collected with saliva, and Dr. Kaye 
replied that it would not.  Saliva has higher yield than buccal scrapings. 
 
 Dr. Horn said that saliva could possibly be relevant for longitudinal work and if blood was not 
collected as part of subsequent collections. 
 




 Dr. Kaye asked about saliva’s utility beyond DNA.  Dr. Bowser said that saliva is being used 
as a biomarker in some contexts. 
 
 Dr. Boylan suggested that saliva is “better than nothing” if a person is not able to contribute 
other biospecimens.  Dr. Gubitz agreed. 
 
 Regarding urine, Dr. Faye pointed out that it is easy to collect and store.  Dr. Bouzyk 
suggested that its ease of collection is an argument to include it in the pilot study. 
 
 Dr. Cross said that many samples and sample types in her biorepository are never used.  
They still have to be catalogued and stored.  Rather than collecting a sample because it is 
easy to collect, it should be collected for a use. 
 
 Dr. Bouzyk added that most biorepositories struggle with publicizing the availability of their 
resources to the investigator community.  He has extracted DNA from urine samples that are 
more than 20 years old.  For the purposes of the pilot study, the more the better.  Further, 
ALS is a rare disorder with a small cohort. 
 
 Dr. Cross said that they are collecting urine now, and 1 study will be using it. 
 
 Dr. Kaye turned to hair and nails.  Dr. Weisskopf noted that they are easy to store. 
 
 Dr. Horton asked about information on exposure that can be gleaned from hair and nails.  
Dr. Weisskopf replied that exposure information for several months and up to 1 year would 
probably be available. 
 
 Dr. Kasarskis said that saliva is a solid “Plan B” if blood is not available. 
 
 Dr. Kaye said that the question was whether they would collect saliva from all participants to 
ensure that a biospecimen was collected from everyone, and collect blood from as many as 
possible.  She asked whether saliva should be collected even when blood is collected. 
 
 Dr. Bowser agreed that saliva should be “Plan B.”  Dr. Bouzyk said that an electronic form 
can first ask about willingness to donate blood and then suggest saliva if the participant 
does not want to donate blood. 
 
 Dr. Kaye then turned to CSF, skin, and muscle.  The panel agreed that CSF is very useful.  
She questioned whether it is practical to collect CSF on a large representative sample of 
people. 
 
 Dr. Berry said that CSF has to be collected in an office by someone who is able and willing 
to do a lumbar puncture.  This process asks more of participants, and many may not be 
willing to provide it. 
 
 Dr. Kasarskis reminded them that there is morbidity associated with CSF.  Headaches are 
common.  Dr. Berry said that there are ways to collect CSF in ways that minimize adverse 
events, and management plans should be in place for adverse events. 
 




 Dr. Bowser said that it might be important for the pilot study to determine the feasibility of 
collecting CSF. 
 
 Dr. Bradley suggested that this collection could be linked with pharmaceutical trials. 
 
 CSF is an important specimen, and it is not impossible to collect in a home setting.  
 
 Mr. Tison said that he would volunteer again for a great cause. 
 
 The panel discussed skin and muscle and agreed that skin can be collected in a home 
setting and does not necessarily require an office visit. 
 
 Dr. Corriveau said that the primary purpose of the skin is fibroblasts.  He wondered about 
sporadic fibroblasts and whether a mutation is involved.  Given the expense and the 
investment already in the field, he was not sure that skin should be a priority specimen. 
 
 Dr. Brujin agreed and reminded the group of the unique modules that accompany the 
samples.  Fibroblasts may not be needed for IPS lines, but they could be needed for another 
application. 
 
 Dr. Bidichandani said that that the point of collecting skin is for fibroblasts, but the point of 
collecting fibroblasts is not only to make iPS cells.  Depending on the genes that are found 
to be mutated in individuals, it is possible to conduct several biochemical assays and cell-
based assays.  They can also be a back-up for DNA, RNA, and proteins. 
 
 Dr. Corriveau said that if the cell biology is desired, then perhaps they should consider 
cryopreserved lymphocytes that do not obligate the immediate production of a cell line. 
 
 Dr. Bidichandani said that epigenetic changes have been found reproducibly in fibroblasts, 
but not in lymphoblasts, in some of the repeat expansions diseases.  Fibroblasts provide a 
tractable model to investigate a number of assays because they are available in huge 
numbers.  He would place fibroblasts high on his list, because a priori it is not known what 
kinds of investigations will be done. 
 
 Dr. Bowser agreed and noted that skin is the only immortalized specimen they are 
collecting.  As they consider future uses for the bioregistry, there is potential value in those 
cell lines, despite challenges with storage and other issues. 
 
 Dr. Kasarskis’s colleagues are using fibroblasts from ALS to study gene regulation and 
enzyme levels.  It is not possible to do this work with postmortem tissues.  The flexibility of 
studying viable cells as fibroblasts is beneficial. 
  





 Dr. Bradley asked whether skin can be cryopreserved without first culturing the fibroblasts.  
The panel was not certain.  Dr. Horn indicated that the answer is “no” with keratinocytes. 
 
 Dr. Berry said that if fibroblasts are put into a repository, then the consent form should 
address whether they can become iPS cells.  If they can be, then the protocol must stipulate 
how they can be shared and used.  Intellectual property considerations are important as 
well.  If fibroblasts can be made, but not iPS cells, then that decision has implications as 
well. 
 
 Dr. Kasarskis noted that the VA consent form covers those points, and patients can opt in or 
out of all of those categories.  The donors are informed that the cells are not going to be 




 Dr. Kaye asked the panel whether additional data should be collected by the National ALS 
Registry above and beyond the current modules and the new modules that will be added on 
additional exposures, occupation, head trauma, electrocution, caffeine use, and pregnancy 
history.  There is some concern that registry participants have not been completing the 
modules.  If people participate in the biorepository, then they will be directed back to the 
surveys and will receive assistance in answering them, if necessary. 
 
 Dr. Kasarskis asked about the military module.  Dr. Kaye answered that the military module 
includes questions about the branch of service and service in a wartime theater. 
 
 Dr. Kasarskis observed that the module is fairly global and wondered whether it could be 
developed more to learn more about types of exposures and environments.  He asked 
whether ATSDR had consulted with epidemiologists in the military.  Dr. Kaye answered that 
the modules have a 5-minute time limit. 
 
 Dr. Horton said that there would be concerns associated with modifying an existing survey.  
Any new questions would need to be presented in a new module. 
 
 Dr. Kaye added that the modules collect lifetime residential exposure, not occupational.  The 
surveys ask about usual occupation and current occupation. 
 
 Dr. Bradley emphasized that it is important to understand residential lifetime exposure.  Dr. 
Kaye said that the new module will ask about lifetime residential history.  It includes the type 
of water and whether the area was urban or rural. 
 
 Dr. Weisskopf asked about “usual” and “current” employment.  It might be possible instead 
to ask specifically about a participant’s military occupation.  This information is important.  
He suggested adding history of traumatic brain injury (TBI) or blast injuries. 
  





 Dr. Kaye said that there are separate questionnaires for TBI and electrocution.  The old 
modules are demographics, smoking and alcohol use, occupation, military service, physical 
activity, family history, and the ALSFRS on a 6-month basis.  The new modules include 
lifetime residential history, exposure to pesticides, exposure to hobbies, TBI and 
electrocution, caffeine use, female reproductive history, a clinical module, and open-ended 
questions on concerns about ALS and insurance. 
 
 Dr. Horton said that ATSDR actively solicits feedback and encouraged the panel to forward 
additional ideas to them. 
 
 Dr. Gubitz said that the modules are comprehensive and cover relevant information without 
making the process too burdensome for patients.  Although familial mutations are rare, the 
family history module does not capture elements of them.  She suggested that one of the 
new models could provide a way for patients to indicate whether they have a familial 
mutation. 
 
 Dr. Kaye said that the clinical module asks whether a patient has undergone genetic testing.  
Dr. Horton said that any question should be answered easily by the patient. 
 
 Dr. Boylan said that the question was kept general because new genes are found all the 
time.  Dr. Gubitz felt that a general question would suffice.  Many ALS patients are well-
educated and know a lot about their disease.  They may want to share this information. 
 
 Dr. McCarty asked about consent to access medical records.  Dr. Kaye answered that all of 
the information is self-reported.  Access to medical records is usually time-limited by the 
IRB. 
 
 Dr. McCarty asked about medication use.  Dr. Kaye said that Stanford advised against 
asking about medication use.  The clinical module asks about RILUTEK®. 
 
 Mr. Tison suggested adding more gradation to the physical activity module, as many ALS 
patients are serious athletes.  Current questions only separate those who engage in little or 
no physical activity from those who engage in more physical activity.  Regarding genetics, 
he suggested asking about second-degree relatives with ALS. 
 
 Dr. Horton said that the issue of physical activity and sports has been raised.  The clinical 
linking mechanism will be able to identify participants who are physically active, and there 
may be a way to query the system so that a researcher could identify a subset of individuals 
and conduct a study based on those who said they were physically active. 
 
 Dr. Berry said that when the biospecimens are collected, they should ask questions about 
the time of day; when the patient last ate, drank, or consumed caffeine; and other germane 









 Dr. Brujin encouraged them to use the materials that were developed as part of the NINDS 
common data elements work. 
 
Size of the Pilot Project 
 Dr. Kaye asked about the size of the pilot project.  What is a reasonable number for a 
feasibility study?  Should they test the idea of doing longitudinal specimens?  What about 
control specimens? 
 
 Dr. Brooks felt that the feasibility pilot should include at least 2 consecutive samples from 
the same person. 
 
 Dr. Kaye confirmed that the samples would be blood.  It is not likely that the CDC IRB will 
approve two collections of CSF.  Since they are conducting a feasibility study, should they 
plan for a large enough sample size to randomize people into groups of 1 sample or 2 
samples? 
 
 Dr. Brujin said that 2 should be collected wherever possible in order to have a comparison. 
 
 Dr. Horton said that part of the study was to determine what can be collected from 
individuals, and how easily.  Dr. Weisskopf agreed that part of the point of the study was to 
determine whether participants were willing to give a second sample.  Dr. Boylan agreed, 
noting that part of testing feasibility is to offer everyone the same options. 
 
 Dr. Kasarskis asked who would administer the consent forms.  Dr. Kaye answered that the 
process is not finalized, but the person collecting the specimen will probably administer the 
consent form.  Participants who indicate interest in participating will receive the form in the 
mail.  The forms will be reviewed by trained interviewers via telephone.  Then the signed 
consent will be obtained at the time of collection. 
 
 Dr. Kasarskis expressed concern that the depth of the information in the consent form would 
be within the scope of knowledge of the person administering consent over the telephone so 
that the IRB will be assured that the patient understands the project completely. 
 
 Dr. Kaye indicated that the types of cells were not included in the consent initially, so the 
process may need to be revisited.  Participants will probably not go to physicians’ offices for 
specimen collection. 
 
 Dr. Kasarskis said that skin samples are operative procedures for most medical centers.  In 
order to get a comprehensive set of samples, face-to-face with a physician may be needed.  
Dr. Kaye said that skin may not be possible to include. 
 
 Dr. Horn asked about training for people who get consent and collect the samples.  Their 
model includes dedicated coordinators that are trained in consenting procedures.  Dr. Kaye 
said that vendors will be utilized, and there will be training packages.  The logistics will be 
addressed separately. 
 




 Mr. Tison said that for timing to get postmortems near term, lower ALSFRS scores may 
need to be targeted.  It also may be necessary to ask about invasive ventilation preference 
and target those opposed. 
 
 Dr. Kaye said that they will engage in targeting for postmortem specimens.  They will have 
the opportunity to participate in all sample types.  The study will target those with lower 
scores on the ALSFRS or who have been in the registry for a longer period of time.  She 
asked about absolute numbers of living persons to include in the study. 
 
 Dr. Horn suggested consulting with a statistician.  Dr. Brujin suggested that they ensure that 
the sample is diverse and to get representation in difficult areas. 
 
 Dr. Kasarskis was concerned that the first pass might include the ALS patients who are the 
most willing to participate and may therefore not be longitudinally representative. 
 
 Dr. Kaye said that all patients will be in the National ALS Registry and have indicated their 
willingness to be contacted for opportunities.  A sample of those people will be contacted.  If 
they want to make comparisons, then they will need a large enough sample. 
 
 Dr. Williamson noted that there will still be a bias within the registry, as the participants will 
have had to indicate their willingness to be contacted for studies.  Dr. Kaye confirmed that 
everyone in the registry has indicated willingness to be contacted. 
 
 Dr. Brujin suggested that they have as large a sample as possible.  Dr. Boylan stressed that 
the sample size would probably be driven by what they can afford. 
 
 Dr. Horton said that if they increase the sample size, they will have to justify the reasoning 
for a larger size than 150.  Dr. Kaye and Mr. Kingon pointed out that 150 is a fairly small 
number. 
 
 Dr. Thurman said that it is important to have sufficient numbers of people who live in remote 
areas far from a referral medical center to determine whether they can be reached.  The 
sample may need to be weighted.  Input from a statistician will be needed, and he 
suggested that a number higher than 150 may be needed. 
 
 Dr. Berry suggested approaching the calculation in a manner similar to a tolerability study in 
a randomized controlled trial. 
 
 Dr. Bouzyk pointed out that large cohorts are needed in case control association studies.  If 
the work is hypothesis-driven or focuses on a familial component, then a few hundred or 
fewer participants may be needed.  It might be worthwhile to draw blood from first- and 
second-degree relatives and build up pedigrees of the ALS patients themselves. 
 
 Mr. Tison asked Dr. Berry whether it would make sense to target a size match with the 
NEALS Biomarker Research Study for longitudinal samples.  Dr. Berry said that it might 
make sense to choose a number that is larger than a biorepository that exists.  NEALS has 
200 patients with early ALS and 50 additional participants with pure upper or lower motor 
neuron signs.  They also include disease controls. 
 




 Dr. Kaye confirmed that there was agreement among the panel that a sample size of 
approximately 300 seemed appropriate. 
 
 Dr. Cross asked whether related individuals in the registry are linked.  It may be important in 
the long-term to capture families.  Dr. Kaye replied that the registry does not ask that 
question, and it would be challenging to do, as a person must be living to be in the registry. 
 
 Dr. Brooks asked what the agency would consider a successful study. 
 
 Dr. Horton replied that the goal of the RFA was to determine whether it was feasible to 
create a biorepository.  They will consult with statisticians to determine a quantitative 
benchmark. 
 
 Dr. Brooks said that they have a capturable sample, as opposed to a convenience sample.  
He proposed that a success would be 2000 patients, as was achieved by Coriell. 
 
 Dr. Gubitz said that Coriell focused on blood only.  Dr. Kaye said that 2000 is not needed for 
a feasibility study.  Dr. Horton agreed that when the biorepository goes live, they want as 
many participants as possible. 
 
 Dr. Kaye said that the pilot study needs enough specimens to determine feasibility for long-
term viability.  They also would like to have enough specimens so that they can also be 
used for research activities if the biorepository does not go forward. 
 
 Dr. Brujin said that if they set a goal of 300, but only capture 200, they should consider the 
outcome that will convince CDC to pursue the project. 
 
 Dr. Kaye said that feasibility includes not only the number of samples, but also how many 
samples were collected per person, the logistics, the costs, and more. 
 
 Mr. Tison suggested collecting the Social Security Numbers of affected relatives to link 
siblings with familial ALS.  Close relatives could easily acquire that information. 
 
 Dr. Boylan understood that one of the underlying interests in the study was geographic and 
demographic representations of the population, which are important statistical 
considerations. 
 
 Dr. Kaye said that other considerations include urban versus rural, race, and gender.  Those 
who self-registered with the Registry may not be as diverse as the population as a whole. 
 
 Dr. Bowser indicated that NEALS collected 200 samples in 2 years.  This pilot study could 
aim to collect at least 300 samples from a geographically dispersed area.  The study may 
not reach 300 samples, but could reach a goal of geographic distribution of samples or level 
of racial or ethnic diversity.  The feasibility could still be a success. 
 
 Dr. Williamson said that statistics will not drive this feasibility study.  Little baseline 
information is available, and part of the purpose of the study is to obtain baseline data in 
order to design studies. 
 














Proximity to CNS  ++  +++  +  +  +  +  +  +  +++  
Less Invasive  ++  +  +++  +++  ++  +  +  +++  +  
Practicality  +++  +  +++  ++  ++  +  ++  +++  +  
Handling/processing  ++  +  ++  +++  +  +  +++  +++  +  
Potential for 
DNA/RNA  
+++  +  +  ++  +++  +++  +  +  +++  
Time for Collection  10-25  30-45  5  5  10-15  15   5   
Longitudinal  +++  ++  +++  +++  NA  NA   +++   
Ease of Collection  ++  +  +++  +++  ++  ++   +++   
Candidate 
biomarkers  
++  +++  +  +  ++  +  +  +  +++  
Goal of Specimen  DNA 
Biom  










Env  Path 
Env  
Future use  +++  ++  +  +  +++  +++  +++  +  +++  
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